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ABSTRACT 
 
 Nicholas Brandon Berry 
 
Regulation of Estrogen Receptor-alpha (ERα) Ubiquitination and Proteasome-
mediated Receptor Degradation
  
Breast cancer is the most common cancer among women, and the majority (~70%) 
express estrogen receptor-alpha (ERα), thereby exhibiting estrogen-dependent growth. 
Antiestrogen therapies block ERα-mediated cell growth, either by blocking ERα function 
or by triggering ERα degradation.  ERα is recognized for degradation by the 26S 
proteasome through the addition of ubiquitin protein tags onto ERα lysine residues. 
However, the specific receptor lysines that are ubiquitinated have not been identified. 
Two receptor lysines, K302 and K303, located in the hinge-region of ERα, serve multiple 
regulatory functions, and we examined whether these residues might also regulate 
receptor ubiquitination or are targets themselves for ubiquitination.  An ERα protein was 
generated that contained lysine-to-alanine substitutions at these two residues. 
Comparisons were made between the unmodified ERα (wtERα) and the mutant receptor 
ERα-K302A, K303A (ERα-AA).  The effect of the proteasome inhibitor MG132, Hsp90 
inhibitor geldanamycin (GA), and ER ligands 17β-estradiol (E2), tamoxifen (OHT), and 
the pure anti-estrogen ICI 182,780 (ICI), were examined for their effect on receptor 
ubiquitination, degradation, and receptor activity.  In the absence of ligand, ERα-AA 
displayed rapid ubiquitination and degradation due to elevated association with the 
ubiquitinylation enzyme CHIP and the proteasome-associated cochaperone Bag1.  E2 or 
ICI induced rapid degradation of wtERα; however, ERα-AA was less efficiently 
degraded by these ligands.  Furthermore, ERα-AA was also resistant to ICI-induced 
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ubiquitination, suggesting that these lysines are ubiquitinated in response to the 
antiestrogen.  ERα-AA activity was decreased in the unliganded state and elevated in 
response to E2, concordant with receptor stability in these two states.  These data provide 
the first evidence that K302/303 protect ERα from basal degradation and are necessary 
for efficient E2 and ICI-induced turnover in breast cancer cells, revealing a previously 
unexplored mechanism for regulating ERα stability and activity. 
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αERKO   estrogen receptor-alpha knock-out mouse 
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ERα-AA    ERα-K302A,K303A 
ERα-RR    ERα-K302R,K303R 
ERβ    Estrogen receptor-beta 
ERE     estrogen response element 
FRAP    fluorescence recovery after photobleaching 
GAPDH    glyceraldehyde-3-phosphate dehydrogenase 
HA     hemagglutinin 
Hsp     heat shock protein 
ICI     ICI 182,780 
LBD    ligand binding domain 
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NLS    nuclear localization sequence 
NR    nuclear receptor 
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PROTAC   Protein Targeting Chimeric Molecules 
RT-qPCR    Reverse transcriptase quantitative polymerase chain reaction 
SCF     Skp1-cullin-F-box protein 
SRC    steroid receptor coactivator 
SERD     Selective Estrogen Receptor Downregulator 
SERM     Selective Estrogen Receptor Modulator 
siRNA     small interference RNA 
wtERα    wild type estrogen receptor alpha 
 REVIEW OF ESTROGEN RECEPTOR LITERATURE 
Discovery of estrogen action 
Dr. Elwood Jensen pioneered the basic understanding of the molecular 
mechanisms of estrogen action, overturning conventional understanding of estrogen 
action and paving the way for the discovery of the nuclear receptor family.  Traditionally, 
biochemists thought a hormone entered a cell, where a series of oxidation and reductions 
reactions with estrogen provided needed energy for the growth stimulation and other 
specific actions shown by estrogens.  Using high specific-activity radiolabeled H3-17β-
estradiol, Jensen revealed the specific localization of estrogen to reproductive tissues as 
well as the binding of the steroid hormone to an immune complex termed “estrophilin” 
(1, 2).   Jack Gorski and others revealed that this binding substance, with which estradiol 
associated without a chemical change, is a true receptor, and was the first steroid hormone 
receptor to be recognized (6, 7).  These receptors were shown to be macromolecules that 
could be extracted from reproductive tissues which, when bound by estradiol, migrated to 
the nucleus where they  activated specific genes by stimulating new RNA synthesis (7, 
8). 
 Using Jensen’s pioneering radiolabeling technique, the presence of estrogen 
receptors in clinical samples and breast cancer cells was able to be determined.  It had 
been known for decades that about one-third of premenopausal women who had 
advanced breast cancer would respond to estrogen blockade brought about by removing 
their ovaries, the source of estrogen, but there was no way to predict which women would 
respond.  ER-rich breast cancers were shown to be more likely to respond to endocrine 
ablation than ER-poor breast cancers (9).  To address this challenge, Dr. Jensen and 
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 Geoffrey Greene, at the University of Chicago’s Ben May Institute, developed polyclonal 
(10) and monoclonal antibodies (9, 10) directed against ER, which enabled them to 
quickly and accurately detect estrogen receptors in breast and other tumors.  This test 
transformed the treatment of breast cancer patients, allowing for rapid 
immunohistochemical determination of breast cancer patient tumor ER status and thus 
the use of hormonal therapy.  This principle remains the basis of determining ER status 
today.   
Estrogen  
 The hypothalamic-pituitary-gonadal (HPG) axis directs integrated function among 
the endocrine organs to coordinate growth, development, and preparation for 
reproduction (11).  GnRH from the hypothalamus stimulates the anterior pituitary to 
secrete FSH and LH, which act on the ovary to promote folliculogenesis and the 
concomitant synthesis of 17β-estradiol (E2) (12).  The naturally occurring estrogens 17β-
estradiol (E2), estrone (E1), and estriol (E3) are all C18 steroids derived from cholesterol.  
After binding to lipoprotein receptors, cholesterol is taken up by steroidogenic cells, 
stored, and used for steroid synthesis.  Synthesis of endogenous estrogens is necessary for 
the development and regulation of reproductive systems, the maintenance of bone 
density, the modulation of cardiovascular system and lipid metabolism.  Estrogens, as 
endocrine hormones, circulate systemically and diffuse into target tissues to exert their 
effects by interacting with steroid receptors, specifically estrogen receptors alpha and 
beta (ERα and ERβ).  In the serum, E2 reversibly binds to sex-hormone-binding globulin, 
a β-globulin, while about 2 to 3 percent of estradiol is free (13).  The free hormone is 
capable of diffusion across cell membranes.    
2
 ESTROGEN RECEPTORS 
 ERα and ERβ are members of the steroid/nuclear receptor (NR) superfamily that 
includes over 150 members.  This family shares a highly conserved structure and 
common mechanisms affecting transcription of a multitude of target genes in response to 
specific physiological and pathological signals (14).  The NR superfamily includes class I 
NRs, the steroid receptors:  glucocorticoid, mineralocorticoid, progesterone, estrogen, 
and androgen (GR, MR, PR, ER, and AR), and the class II NRs:  retinoic acid receptor, 
retinoid X receptor, vitamin D receptor, thyroid receptor, and peroxisome proliferator 
activated receptor (RAR, RXR, VDR, TR, and PPAR).  NRs function as dimeric 
transcription factors; class I NRs dimerize with themselves, while class II receptors 
typically dimerize with RXR.  The NR superfamily also includes numerous “orphan 
receptors”, known as such because their endogenous ligands are unknown.  NRs act as 
intracellular transcription factors that, on association with ligand, bind to hormone-
responsive target genes to modulate their expression.  
 ERα (http://www.genenames.org/data/hgnc_data.php?match=ESR1) was first 
cloned from human breast cancer cells in 1986 (15), while ERβ 
(http://www.genenames.org/data/hgnc_data.php?match=ESR2) was discovered 10 years 
later (16).  These two receptor subtypes vary in structure, and their encoding genes are on 
different chromosomes. ERα been mapped to chromosome 6 at the boundary between 
6q24 and 6q27.  ERβ maps to chromosome 14 at locus q23.2.  The NR family shares 
multiple conserved functional domains and they exert their effects using relatively similar 
mechanisms.   
3
 17β-estradiol (E2) is the cognate ligand for ERs, and has the highest endogenous 
ligand binding coefficient (Kd) ~0.28 nM (17) (Figure R1). Both estrone and estriol bind 
ERs but with slightly lower affinity compared to E2 (18).  4-hydroxytamoxifen, the 
active metabolite of tamoxifen, has 100-fold greater affinity for ERα than E2, and 
directly competes with E2 for ERα binding (19).  As ERα and ERβ share little homology 
in the ligand-binding domain (20), some ligands bind to the two receptors with different 
affinities.  For example, raloxifene binds with higher affinity to ERα whereas several 
environmental pollutants, such as the alkylphenols, have a higher affinity ERβ (21).  The 
short-acting 17α-estradiol and the biologically weak estrone have a higher affinity for 
ERα, while the majority of phytoestrogens bind with higher affinity to ERβ (22).  The 
biological responses to phytoestrogens are therefore believed to be exerted through ERβ 
signaling (21).  
 
ERα Structure 
 
The ERα protein contains six domains, A–F, which are conserved to varying degrees 
among members of the NR superfamily (23) (Figure R2).  The N-terminal A/B domain is 
the least conserved among all members and demonstrates only 17% identity between 
human ERα and ERβ (24). This region contains a constitutive (ligand-independent) 
transcriptional activation function (AF1), the activity of which is regulated by growth 
factors via signal transduction cascades.   The C domain is the most highly conserved 
among the different members of the family.  This region encodes two zinc fingers that 
possess 97% homology between the ERα and ERβ genes (24, 25).  These zinc fingers 
form a helix-loop-helix motif and function to bind ERs tightly to specific DNA sequences 
called estrogen response elements (ERE).  The sequence of the consensus ERE element is 
4
  
Figure R1.   Estrogen Receptor ligands 
1.  The endogenous ER ligand 17β-Estradiol 
2.  SERM  4-hydroxytamoxifen                   
3.  Pure antiestrogen (SERD)  ICI 182,780 
4.  SERM raloxifene    
                                      
 
1.  17β-estradiol (E2)          
 
 
 
  
    2.  4-hydroxy tamoxifen (OHT) 
 
 
 
       
3.  ICI 182,780 (ICI; Fulvestrant; Faslodex ®) 
 
 
 
 
4.  Raloxifene     
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 GGTCAnnnTGACC (26).  As both ERα and ERβ bind to the same ERE, it is not 
suprising that they share such high homology in the DNA binding domain.   
The D domain, or hinge-region, separates the DNA binding domain from the ligand 
binding domain.  This region contains sequences for receptor dimerization and three 
prototypical nuclear localization sequences (pNLS) (27, 28).  Although the D domain 
possesses high homology throughout the nuclear localization sequences for most nuclear 
receptors, the overall homology of this region is only 30% (24).  The hinge region 
interacts with nuclear coregulatory proteins including L7/SPA, NCoR, and SMRT (29).  
Recent reports have placed several post-translational modifications at the hinge-region, 
including acetylation of ERα hinge-region lysines K266 and K268 (30), and K299, K302, 
K303 (31). 
  Sumoylation is also reported to occur on these same residues (32).  Phosphorylation of 
S305 has been shown to regulate receptor acetylation at lysine K303 (33), revealing 
multiple mechanisms for receptor regulation in this region.  A recent report has revealed 
monoubiquitination of K302 by BRCA1/BARD1 (34), adding further complexity to this 
regulatory region.  The regulatory role of hinge-region lysines 302/303 on receptor 
ubiquitination and degradation serves as the basis of my thesis work.   
 The E domain contains the ligand-dependent activation function domain (AF-2) 
domain, which includes the ligand binding domain (LBD).  The LBD is a compact 
structure consisting of 12 α-helices with a pocket into which the ligand fits (35, 36).  
Amino acids within the LBD interact with ligands, securing them within the pocket.  
Ligand binding alters the conformation of the LBD, bending helix 12 (H12), forming a 
lid over the pocket and trapping the ligand in a hydrophobic environment.  The precise 
7
 positioning of H12 over the ligand binding pocket is dictated by the nature of the bound 
ligand (35).  The position of H12 also determines whether ERα will be activated or 
repressed by the bound ligand.  In this manner, H12 functions as a molecular switch, 
sensing the nature of the receptor ligand and translating this information into a receptor 
conformation that triggers a cellular response to the altered receptor structure (35, 36).   
For example, when E2 is the ligand, H12 is rotated into a position that exposes a surface 
on the LBD with which coactivator proteins interact, resulting in receptor-induced 
transactivation.  On the contrary, antiestrogens like OHT or ICI, when bound to ERα, 
position H12 in conformations that occlude the coactivator recognition domain, resulting 
in transcriptional repression.  These aspects of ligand binding and interaction with H12 
make this α-helix indespensible for AF2 function (37).  The ligand-binding domain best 
serves to distinguish ERα and ERβ, as only 55 percent of the amino acid sequence is 
shared within this region (24).  However, each binds estradiol with nearly equal affinity, 
although xenoestrogens and synthetic ligands have differential binding affinities (22).    
 The C-terminal F domain is unique to ER among the nuclear receptors (38), but is 
not well conserved among the ERs of different species nor between the ERα and ERβ, 
sharing only  ~18% homology (24). Studies using truncated ERα mutants (missing the C-
terminus) have indicated a role for the F domain in modulating transcriptional activity of 
ERα when complexed with mixed agonist/antagonist ligands, suggesting this region may 
function alongside helix 12 to influence coregulator protein recruitment.  This region may 
also facilitate receptor dimerization (39-41) or cross talk with signal transduction 
pathways (42).  The F domain possesses a putative PEST (proline (P); glutamic acid (E); 
8
 serine (S); threonine (T)) sequence, which is thought to promote protein degradation.  
However, the ERα PEST sequence does not appear to influence receptor turnover (43).   
 
ERβ 
 Studies with mice lacking ERα (ERα knock-out mice; αERKO mice) have shown 
that ERα but not ERβ is essential for proliferation in mammary gland, uterus, and 
prostate (44, 45).  ERβ has been shown to antagonize the stimulation by ERα, (46) 
revealing a ying-yang relationship for these two receptors.  ERα typically drives cell 
proliferation while ERβ influences differentiation of dividing cells (46).  Reproductive-
related cancers typically overexpress ERα, revealing the importance of maintaining an 
appropriate balance of ERα to ERβ (47).  ERβ-selective agonists are considered anti-
cancer compounds (phytoestrogens, etc), further suggesting ERβ signaling is necessary to 
offset ERα-mediated cell proliferation. 
Perhaps the most significant disparity between ERα and ERβ is the tissue 
distribution.  Although there is some overlap, the endometrium, mammary gland, testis, 
pituitary, liver, kidney, heart, and skeletal muscle contain mostly ERα, whereas ERβ 
transcripts are significantly expressed in in many nonclassic estrogen target tissues, 
including the kidney, intestinal mucosa, lung parenchyma, endothelial cells, and prostate 
gland (22, 24, 48, 49).  Relatively equal and overlapping expression of ERα and ERβ is 
seen in the epididymis, thyroid, adrenals, bone, and various regions of the brain (22, 48, 
50).   
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 Membrane-bound ERα  
 In addition to conventional nuclear receptors, ERα can be anchored to the cell 
membrane.  Membrane-bound ERα originates from the same gene as nuclear ER (51), 
and through palmitoylation of ERα C447, ERα is inserted into plasma membrane caveoli 
(52).  These receptors cannot translocate to the nucleus but can elicit rapid, non-genomic 
actions through the cytosol.  In breast cancer and endothelial cells, nuclear and membrane 
ERs were found to be the same proteins, providing evidence that classical ERα mediates 
rapid signals induced by E2 in these cells (53).   
Alternativly, reports suggest that G protein-coupled estrogen receptor 1 (GPR30), an 
orphan receptor, is the membrane-bound ERα, and though it has high affinity for E2 and 
antiestrogens, it is otherwise unrelated to ERα (54).  GPR30 is structurally unrelated to 
ERα as it is a 7-transmembrane protein that functions as a G-protein coupled receptor and 
therefore localized to the plasma membrane (55, 56), or the endoplasmic reticulum (57).  
This membrane-bound ERα has been suggested to be responsible for the numerous rapid 
effects of E2 on a number of target tissues, including vasodilation of blood vessels, 
calcium signaling in bone (58), and induction of numerous secondary messenger 
molecules such as cyclic AMP, IP3, and phospholipase C (58). 
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 ESTROGEN ACTION ON TARGET TISSUES  
The influence of estrogen is not restricted to reproduction and reproductive 
tissues.  Estrogen is synthesized and secreted as endocrine steroid hormones, thereby 
exerting systemic effects, both positive and negative, on on hormone-sensitive tissues 
(Figure R3).   
 
Fetal development 
 The female reproductive tract is the default phenotypical sex and will differentiate 
and develop normally in the absence of ovaries and adrenal glands (67).  Therefore, 
estrogen is not required for differentiation and initial development of the female 
reproductive tract, whereas testosterone is critical to differentiation of the male genitalia 
(68, 69).  Estrogen receptors are expressed during development of fetal brains of both 
males and females, however estrogens are only produced in fetal males due to 
aromatization of testosterone secreted by the neonatal testis at specific stages during 
development (70).  Activation of ERα in males leads to neural development and 
differentiation resulting in morphological and biochemical sex differences (71).  
Exposure of females to exogenous estrogen during development also masculinizes the 
brain (72).  Other actions of testosterone on sexual differentiation of the brain are 
mediated by androgen receptors that, like estrogen receptors, are also expressed equally 
in male and female brains but are differentially occupied in males because of the 
testicular secretion of testosterone during perinatal development (71).   
 Because the developing brains of both sexes are highly sensitive to gonadal 
hormones, the fetus must be protected from maternal and endogenous estrogens until 
developmentally appropriate.  The developing fetus therefore expresses α-fetoprotein 
11
Figure R3. Effects of Estrogens in Different Organ Systems 
Estrogens have neuroprotective effects and reduce perimenopausal mood fluctuations in 
women.  Estrogens are arterial vasodilators and may have cardioprotective actions. In the 
liver, estrogens stimulate the uptake of serum lipoproteins as well as the production of 
coagulation factors.  Estrogens also prevent and reverse osteoporosis and increase cell 
viability in various tissues.  When applied topically, estrogens increase skin turgor and 
collagen production and reduce the depth of wrinkles.  These benefits are offset by the risk 
that estrogens stimulate growth of endometrial and breast tumors.  Adapted from Gruber et al.  
NEJM 2002 (5). 
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 (AFP), which binds estradiol and prevents hormonal stimulation (73).  The capacity to 
produce and utilize estrogens clearly exists before birth, as the fetal ovary expresses 
aromatase and ERα (74).  A key element in understanding how xenoestrogens exert 
teratogenic effects was realized when it was discovered that AFP does not bind synthetic 
estrogens such as diethylstilbesterol (DES) (73); DES is therefore capable of bypassing 
AFP-mediated estrogen blockage and stimulate brain sexual differentiation (73).  Many 
insights into actions of estrogens on brain development have come from studies of 
offspring of mothers exposed to DES during pregnancy, while other studies have 
revealed that prenatal DES exposure can alter general personality and altered patterns of 
sexual behavior in adolescence and adulthood (75, 76).  DES is not an androgen, 
although DES has been reported to have a masculinizing effect (76), and some DES-
exposed women show elevated testosterone levels as adults (75).  DES induces genetic 
imprinting and epigenetic silencing of tumor suppressor genes and is implicated in the 
development of breast and uterine cancer (77).  Frighteningly, DES-induced epigenetic 
events and hormonal response reprogramming have been shown to exert physiological 
effects to generations well beyond the initial fetal and maternal exposure.  The US Center 
for Disease control maintains information and support for DES-treated women, children 
exposed in utero, and their offspring (http://www.cdc.gov/DES/). 
 
Ovary  
 Puberty in girls is initiated by low-amplitude nocturnal pulses of gonadotropin, 
stimulating steroidogenic enzymes that raise serum E2 concentrations (78).  E2 
production varies cyclically during menstrual cycles, with the highest rates and serum 
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 concentrations in the preovulatory phase, resulting in follicle maturation, rupture, and 
oocyte release (79).  The precise roles of estrogen in ovarian function has been 
extensively studied using ER and aromatase knockout animal models (50, 80-82).  There 
are defects in ovulation in both αERKO and βERKO mice.  αERKO mice are anovulatory 
and βERKO mice have a severe reduction in ovulation (50, 80), and both αERKO male 
and female mice are infertile (50).  Both ERα and ERβ are therefore required for the 
correct functioning of the ovaries.  The ovarian defect in αERKO mice can be corrected 
by normalization of luteinizing hormone levels (50, 82), which suggests that ovarian 
defects are indirectly related to the loss of estrogen feedback on the pituitary.  In double 
knockout mice (αERKO/βERKO), the females have ovaries that contain seminiferous 
tubule-like structures that are filled with Sertoli-like cells, and the males are infertile 
because of a reduction in the number and motility of epididymal sperm, a phenotype 
similar to that in male αERKO mice (81). 
 
Uterus  
 Several reports describe the initial appearance of ER immunoreactivity in the 
developing uterus as early as fetal day 15 (83).  ER was first detectable in mesenchymal 
cells, whereas induction in the epithelial cells occurs during the late fetal stages and 
increases significantly during the neonatal period (83).  The fully developed uterus is 
composed of many heterogeneous cell types comprising three major anatomical 
compartments, the outer myometrium, endometrial stroma, and luminal/glandular 
epithelium.  Under the influence of FSH from the anterior pituitary, the ovarian follicular 
cells produce estrogen, stimulating early estrogen-responsive genes c-fos and c-jun, 
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 which results in proliferation, increased blood flow, and water retention in the uterus (84, 
85).  The importance of ERα in the uterus is evident from the extremely small uteri in 
αERKO mice and the almost complete inability of this tissue to respond to E2.  ERβ may 
be responsible for some estrogenic stimulation in αERKO mice, as ERβ is present in the 
uterus (86), particularly in the stroma.  The transformation of the uterine stroma in 
response to implantation of the embryo (decidualization) is normal in αERKO mice, 
indicating that ERα is not involved in this process, and may be mediated in part by ERβ 
(87).  The uteri of immature βERKO mice are hypersensitive to the proliferative actions 
of E2 (86), recapitulating the hypothesis that ERβ modulates growth effects mediated by 
ERα. 
 Using αERKO tissue recombination techniques, estrogen-induced proliferation in 
the uterine epithelium was shown to occur through an indirect mechanism involving 
activation of ERα in the underlying stromal cells (88).  Clarification using similar tissue 
recombination techniques, the stromal response was shown to occur only if the overlying 
epithelium expressed ERα (89).  ERα is temporally down-regulated in the epithelia while 
simultaneously up-regulated in the uterine stromal compartment, suggesting ERα plays a 
role in early events associated with E2-induced cell proliferation of the uterine epithelia 
(85).  Based on these results, and with what is currently known about ERα biology, these 
results suggest that early epithelial stimulation (and subsequent receptor loss) precedes 
ERα-mediated signals transduction to the underlying stroma, which by upregulation of 
ERα, may signal through ER-dependent pathways.  Indeed, an extension of earlier 
αERKO tissue recombination studies revealed that the uterine epithelia are directly 
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 stimulated by E2 and that the epithelia stimulate stromal cell proliferation by transmiting 
an epithelial ERα-dependent, systemic factor to the underlying stroma (90).   
 
Breast 
 In mammals, the mammary gland is essentially undeveloped at birth and does not 
undergo full growth until the completion of puberty and remains undifferentiated until 
pregnancy and lactation. Development of the mammary gland may be divided into five 
distinct stages: embryonic and fetal, prepubertal, pubertal, sexually mature adult, and 
pregnancy/lactation (59).  The later four stages of mammary gland development occur 
after birth and terminate in a gland capable of milk production. These stages are strongly 
regulated by the endogenous ovarian steroid hormones and are characterized by massive 
growth of the glandular ducts that emanate from the nipple until they have progressed 
through the fat pad composing the bulk of the breast. Upon pregnancy and the onset of 
lactation, the gland undergoes dramatic differentiation to produce milk-secreting 
structures, termed alveoli, throughout the ductal network (59). 
  The lobular units of the terminal ducts of the breast tissue of young women are 
highly responsive to estrogen.  The density of breast tissue and ERα expression is highest 
in the follicular phase of the menstrual cycle and falls after ovulation (60).  In the normal 
breast, there appears to be a discordance between cells that express ERα and those that 
are actively proliferating (61, 62).  Cells that contain proliferation markers (cyclin A, 
Ki67, or proliferating cell nuclear antigen (PCNA) do not appear to express ERα (63, 64).  
As E2 stimulates cellular proliferation of the mammary ductal epithelium (65), the basic 
question was raised:  How do breast epithelial cells respond to E2?  The first proposed 
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 mechanism, using αERKO mice, revealed that E2 stimulated ERα in stromal cells (66).  
According to that study, stromal-derived growth factors would then interact with growth 
factor receptors on epithelial cells and stimulate their proliferation.  However, these 
findings do not agree with the clinical responsiveness of epithelial-derived ERα-positive 
breast cancers to anti-estrogen therapy, raising the need for re-evaluation and clarification 
of this important issue.  Furthermore, the original αERKO mouse was found to express a 
shorter isoform of ERα and was therefore not entirely ERα null (67).  Recent findings by 
Feng et al. provide a more direct explanation of E2 action in the breast.  Using a novel 
mammary gland-specific ERα knockout mouse, expression of ERα in the mammary 
epithelia was found to be required for ductal and alveolar morphogenesis, as well as 
mammary fat pad infiltration and terminal end bud formation (45), providing strong 
evidence that E2 acts directly through ERα in breast epithelia.  Together, results from 
αERKO tissue recombination experiments (68) and mammary gland-specific αERKO 
mice (45),  a common mechanism has been established in which estrogen stimulates 
epithelial growth and underlying stroma through an epithelial ERα-dependent pathway.   
 
Liver  
 Estrogen and estrogen-like compounds are extensively metabolized in the liver 
into catechol and methoxylated estrogens (100).  Estrogens undergo secondary 
metabolism in the liver resulting in conjugation via sulfation or glucuronidation, allowing 
excretion into the bile or urine (101).  Hydrolysis of these conjugates by the intestinal 
flora and subsequent reabsorption of the estrogen result in an enterohepatic circulation.  
Estrogen can acti directly on the liver, increasing lipoprotein receptors (28, 54), resulting 
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 in a decrease in serum concentrations of low density lipoprotein cholesterol (102).  
Although ERα-negative, ERα-transfected HepG2 liver cancer cells are commonly used to 
screen for estrogenic compounds as well as determine the hepatic enzymes that are 
responsible for generating functionally estrogenic or antiestrogenic metabolites of novel 
compounds (103).    
The active metabolite of tamoxifen; 4-hydroxy-tamoxifen (OHT) is catalyzed by 
the liver P450 enzyme CYP2D6 (104).  Interestingly, OHT is a minor metabolite, and the 
4-hydroxy-N-desmethyl-tamoxifen metabolite (endoxifen), also catalyzed by CYP2D6, is 
the major metabolite of tamoxifen and is essentially equivalent in antiestrogen activity as 
OHT, suggesting this major metabolite contributes to the overall activity of tamoxifen 
(105, 106).  Patients with CYP2D6 polymorphisms who were coadministered 
antidepressants and other drugs that are CYP2D6 inhibitors (paroxitene, others) had 
significantly lower plasma concentrations of tamoxifen and its metabolites (107).  
Polymorphic CYP2D6 patients also have fewer hot flashes associated with tamoxifen 
treatment, but have a higher recurrence rate, presumably due to lower activation of the 
parent tamoxifen drug (108, 109).   
 
Bone 
 Both osteoclasts and osteoblasts express ERα and are direct targets for estrogens 
(110, 111).  Bone is a dynamic tissue that is constantly being resorbed to serve as a 
mineral source for the body and remodeled to replace this reservoir as well as to maintain 
skeletal strength. Osteoporosis is a defined pathology characterized by a loss in bone mass 
and strength and is believed to be due to a disruption in the equilibrium between bone 
resorption and formation (112).  Estrogens directly inhibit the function of osteoclasts (i.e. 
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 “hardens the target”), and are therefore classified as antiresorptive agents (113).  E2 may 
exert this effect by inhibiting PTH-induced cAMP formation thereby blocking the ability 
of parathyroid hormone (PTH) to stimulate osteoclast formation (114). 
Numerous other studies have provided considerable evidence that both estrogen and 
testosterone both prolong the lifespan of the osteoblast by inhibiting osteoblast apoptosis 
(115).  Sex steroid effects on osteoblast apoptosis appear to be mediated by activation of 
the Src/Shc/ERK signaling pathway (115).  Steroids also suppress osteoclast 
development  and survival, mediated through suppression of RANKL (116, 117) and 
induction of the Fas/FasL pathway (113).  Estrogen also regulates the production of 
additional cytokines in osteoblasts which signals to modulate osteoclastic activity in a 
paracrine fashion (118). 
   In mice, though ERα appears to be the major receptor in most estrogen target 
tissues including bone (119), neither clear bone loss nor high bone turnover is detectable 
in αERKO or αERKO/βERKO double-knockout females (120, 121). This unexpected 
maintenance of bone mass in female mutants is presumed to be due to unphysiologically 
elevated levels of other osteoprotective hormones, namely androgens.  Systemic defects 
in the hypothalamus caused by ER inactivation were shown to impair the negative 
feedback system of hormone production leading to an excess of androgens (120).  The 
anabolic effects of androgens mediated by the androgen receptor (AR) are evident in 
female mice (119, 122).  
 Upwards of 200-fold differences in ERα-expression level have been noted 
between breast and bone cells (123), due in part to preferential utilization of the distal 
ERα F promoter, which lies approximately 117 kb upstream of the ERα transcription start 
19
 site (124).  Interestingly, use of this promoter commonly results in splicing of the 5’ UTR 
of ERα to the splice acceptor site in exon 2, effectively skipping exon 1 and resulting in 
the formation of a shorter ERα.  The translation of this variant mRNA results in the 
expression of the 46-kDa ERα  isoform (123, 124) .  Whereas the ERα-46 corresponds to 
approximately one-third of the transcripts expressed in osteoblasts,it represents around 
one-tenth of the total ERα mRNA transcripts in MCF7 cells (124).  In apparent 
compensation for the lower ERα expression level seen in bone, ERα-46 can form 
heterodimers with full-length ERα (ERα-66) as well as homodimerize.  Homodimers 
show a higher affinity for an ERE than ERα-66 dimers.  Furthermore, the ERα-46/66 
heterodimer forms preferentially as compared to the ERα-66 homodimer (123, 124), 
possibly allowing minimal ERα expression to accomplish high levels of estrogen 
response.  Regardless of the relative expression level of ERα in bone, the FDA approval 
of raloxifene, a selective ERα modulator (SERM), for ther treatment of osteoporosis 
clearly highlights the contribution of estrogen and ERα signaling in regulating bone 
density.  Membrane-bound ERα has also been implicated as a mediator of rapid E2 
effects in bone such as rapid calcium signaling (60).  E2 rapidly causes the influx of Ca2+, 
and elevated IP3, cAMP, cGMP, and diacylglycerol formation (125, 126). A cell-
impermeant E2 conjugate demonstrated the cell-surface ER-mediated stimulation of 
alkaline phosphatase in chondrocytes (127).   
 Aromatase is also expressed in osteoblasts and chondrocytes (128), and aromatase 
activity in cultured osteoblasts is comparable to that present in adipose tissue (129). Thus, 
it appears that in bone, local aromatase expression is a major source of E2 and 
participates in the maintenance of mineralization.  Several males with aromatase 
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 deficiency have been described (130, 131), with identical skeletal phenotypes as the ER 
knockout male (132), revealing the importance of aromatase and localized estrogen 
action in bone.  Osteopenia is evident in a male patient genetically deficient in ERα 
(132), and in patients with aromatase mutations (133). 
 Because estrogen has pleiotropic effects on virtually all aspects of osteoclast 
development, activity, and lifespan, it is not surprising that the consequence of estrogen 
deficiency in humans is a marked stimulation of bone resorption (134).  In bone extracts 
from postmenopausal women with osteoporosis, the concentrations of interleukin-6, 
interleukin-1, and TNF mRNA were high (135), which have been shown to stimulate 
osteoclast differentiation (136).  A single case exists in which a human man lacks 
functional estrogen receptors (132).  He was found to have severe osteoporosis and 
reduced fertility, with no target-tissue responses to estrogen therapy. Genetic analysis 
showed that the patient was homozygous for a mutation in the second exon (R157X) of 
the ER gene, generating a premature stop codon.  This man was exceptionally tall due to 
incomplete epiphyseal closure and continued linear bone growth, revealing the 
importance of ER is epiphyseal closure (132).  Furthermore, despite elevated testosterone 
levels, high rates of bone resorption and skeletal osteopenia were evident (132).  Similar 
to the observations in the αERKO mice, these findings reveal E2 action in both bone 
maturation and mineralization.   
 Osteoporotic bone loss is the result of high bone turnover in which bone 
resorption outpaces bone deposition (137, 138). This imbalance in bone turnover that is 
induced by estrogen deficiency in women and female rodents can be ameliorated with 
bio-available estrogens including selective estrogen receptor modulators (SERMs) (139).  
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 Current evidence supports the hypothesis that excess bone resorption occurs in the 
postmenopausal years, acting to strip the bone of mass and further remove the foundation 
upon which new bone may be formed (112). Several therapies are known to reduce the 
postmenopausal increases in bone resorption, including the intake of calcium and vitamin 
D, calcitonin, bisphosphates, and estrogens (112).  Breast cancer bone lesions span a 
spectrum in which the majority are osteolytic, but up to 15% are osteoblastic or mixed 
(140).  Both osteoblastic and osteolytic bone metastases lead to numerous skeletal 
complications, including bone pain, hypercalcemia, pathologic fractures, and spinal cord 
and nerve compression syndromes (141). Such complications increase morbidity and 
diminish quality of life in these patients.  Tumor cells and bone cells may rely on the 
same signaling pathways and transcription factors to facilitate their cooperative 
interactions at sites of metastases. This phenomenon has been suggested to represent 
"osteomimicry" on the part of the tumor cells (142) by expressing bone proteins such as 
bone cell surface proteins and secreted factors.  Osteolytic MDA-MB231 breast cancer 
cells express PTHrP which may allow breast cancer cells to grow into the bone 
microenvironment by stimulating the bone resorption axis (143), suggesting breast cancer 
cells may possess or aquire similar signaling pathways to facilitate metastasis to bone.   
 
  Cardiovascular 
 There exists a remarkable gender-related contrast in the risk of cardiovascular 
disease. Women generally possess a greater incidence of the multiple risk factors 
associated with cardiovascular disease when compared with men, e.g., obesity, diabetes, 
elevated blood pressure, and plasma cholesterol, however, epidemiological studies 
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 indicate their relative risk of developing this disease is significantly lower (69, 70). It is 
now believed that the protective factor against cardiovascular disease in females is their 
inherently increased exposure to estrogens (69, 70) 
 Estrogens are thought to be natural vasoprotective agents and participate in 
maintenance of the cardiovascular system (71), mediated through expression of ERα in 
smooth-muscle cells of coronary arteries and endothelial cells (72).  Estrogens may exert 
vasoprotective effects by causing short-term vasodilation through formation and release 
of nitric oxide and prostacyclin in endothelial cells (73).   E2 has been shown to 
decrease LDL and inhibit plasminogen activator and vasorestrictive peptides while 
increasing HDL and VEGF synthesis (74, 75).   A protective role of estrogens against 
atherosclerosis is suggested by the finding that estrogen treatment reduced the 
progression of coronary-artery atherosclerosis in oophorectomized monkeys, though it 
does not appear that E2 has an effect on preexisting plaques (76).  An unclarified role 
remains whether estrogen treatment during the postmenopausal period prevents 
atherosclerosis (77).  Favorable findings from epidemiologic studies are counter-balanced 
by the lack of benefit of estrogen seen for protection against cardiovascular disease 
(Heart and Estrogen/Progestin Replacement Study) (78).   
 
Central Nervous System 
 The most important role of estrogens in the brain is feedback control of the 
menstrual cycle.  In the adult, estrogens exert a neuroprotective and supportive effects on 
the central nervous system, which is most evident later in life (79, 80).  Some 
epidemiologic data suggest that in postmenopausal women, estrogen deficiency is 
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 associated with a decline in cognitive function and an increased risk of Alzheimer’s 
disease (81).  Unfortunately, estrogen administration does not appear to have a beneficial 
effect in women with established Alzheimer’s disease (82). 
 Recently, nuclear receptor gene expression has been mapped according to their 
temporal and spatial, and functional aspects in the mouse brain (83).  This project has 
generated a unique, comprehensive dataset, that covers both the quantitative and spatial 
aspects of NR gene expression in the adult mouse brain, and is available online in the 
form of an interactive database (http://www-mci.u-strasbg.fr/mousepat/), allowing for 
data mining to potentially reveal the role of specific nuclear receptors in brain 
development, function, and behavior.  ERα and ERβ appear to have distinct roles in the 
brain.  Behavioral studies with αERKO and βERKO mice show that ERα mediates 
aggressive and sexual behavior whereas ERβ regulates emotional and cognitive behavior 
(84-86).   
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 ESTROGEN AND BREAST CANCER RISK 
In 1896, George Beatson reported that removal of the ovaries from premenopausal 
women with advanced breast cancer produced a dramatic decrease in tumor size and 
improved the patient’s prognosis (87).  Since then, a substantial amount of evidence has 
accumulated to demonstrate that estrogens play a major role in the etiology and 
progression of breast cancer (88-91).  Beginning in the early 1970s, studies began 
reporting significant increases in incidence of endometrial cancer in Western caucasian 
women who had undergone estrogen therapy (92), triggering investigation that continues 
to this day into what levels of estrogen exposure are considered safe.  The concern that 
postmenopausal hormone replacement therapy (HRT) may cause breast cancer has lead 
to an enormous volume of research in epidemiology, endocrinology and tumor cell 
biology.  Whether there exists a positive correlation with the risk of breast cancer and 
prolonged use of synthetic estrogen and progestin contraceptive pills remains 
controversial (93-95), and is further complicated by the influence that environmental 
exposures, geography, diet, body weight, and genetics also play in individual risk of 
developing breast cancer (96).  Polymorphisms in the genes coding for steroidogenic 
enzymes influence estrogen production and should also be taken into consideration for 
individual response to contraceptives and HRT and their respective increase in cancer 
risk (97, 98).  Based on these findings, a prudent and carefully individualized therapeutic 
approach to contraceptives and HRT is warranted.   
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 CLINICAL MANAGEMENT OF BREAST CANCER 
 Breast cancer is the most common cancer and the second leading cause of cancer 
mortality among women.  More than 214,000 women were diagnosed with breast cancer 
and with an estimated 41,430 related deaths in America in 2006 (http://www.cancer.org/).  
Thankfully, these statistics represent an overall decline in new cases and related deaths, 
primarily attributed to the results of the 2002 Women's Health Initative (WHI) study, 
which recommended that women stop taking the hormones Premarin and Provera (99).  
The decrease in numbers was greatest in ER+ breast cancers.  
 Numerous studies have been carried out concerning the levels of ER and PR in 
neoplastic breast tissue and the prognostic value that these parameters may provide (100, 
101).  The consensus is that ER status is a clear predictor of response to hormone therapy 
(102).  Reports indicate that more than 70% of primary breast tumors are ERα-positive 
and exhibit estrogen-dependent growth (101) while the remainder of mammary tumors 
are often ERα-negative and exhibit aggressive, estrogen-independent growth (100). 
 
SERMs 
 Early studies showed reduction in breast tumor growth following adrenalectomy 
(9) or ovariectomy (87).  With the discovery of ER and estrogen action, hormone therapy 
has replaced aggressive surgery as the preferred treatment for ER-positive breast cancers.   
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 Dr. Jensen, known for concluding his lectures in verse, neatly summed up decades of his 
discoveries: 
 
“A lady with growth neoplastic 
Thought surgical ablation too drastic. 
She preferred that her ill 
Could be cured with a pill, 
Which today is no longer fantastic.”  
  
 The term “selective estrogen-receptor modulator” (SERM) was introduced to 
define nonsteroidal ligands such as tamoxifen that antagonize the action of estrogen in 
some tissues, such as the breast, and mimic its action in others, such as the uterus. Among 
postmenopausal women, the agonist action of estrogen is desired in bone for the 
maintenance of density and in the cardiovascular system and brain for the maintenance of 
function, but not in the breast or endometrium. 
 Tamoxifen has been the first-line standard therapy for ERα-positive breast cancer 
treatment for the past 40 years (103).  Tamoxifen exerts its antiestrogenic effect by 
competing with estrogen for ligand binding with ERα, causing attenuated transcription of 
estrogen-responsive genes that are involved in the development and growth of breast 
malignancies.  Unfortunately, a side effect of tamoxifen therapy is the increased risk in 
the development of endometrial carcinoma.  Alternative SERMs like raloxifene retain the 
beneficial estrogenic effects on bone and lipids but are not estrogenic in the uterus (104).  
 
SERDs 
 Inevitably, tumors develop resistance to tamoxifen.  This occurs via multiple 
mechanisms but it appears it is not simply due to loss of ER expression (105).  This, in 
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 turn, provides a rationale for continued hormone treatment after tamoxifen resistance has 
developed.  However, new endocrine therapies must lack cross-resistance with prior 
treatments. Of the SERMs that have been developed, none have shown clinically relevant 
activity following development of resistance to tamoxifen (106-110).  ICI 182, 780 
(fulvestrant, or Faslodex) belongs to a new class of ERα antagonists that rapidly triggers 
ERα protein degradation and is thereby classified as a Selective Estrogen Receptor 
Downregulator (SERD).   
 This mechanism of action of fulvestrant is different from that of tamoxifen, 
reducing the risk of cross-resistance, which allows this drug to have an important role in 
the hormonal treatment of breast cancer.  Fulvestrant competitively binds to ERα thus 
preventing endogenous estrogen from exerting its effect in target cells with no known 
agonist effects (111, 112).  Fulvestrant causes ERα downregulation and reduced shuttling 
of ERα from the cytoplasm (113), and increased receptor immobilization in the nuclear 
matrix (114, 115).  For patients who have progressed on tamoxifen, fulvestrant produces 
good response rates (116).  Fulvestrant is therefore considered second-line therapy for 
treatment of ER+ breast cancers that have failed tamoxifen therapy.   
 
Aromatase Inhibitors 
 At menopause, the synthesis of ovarian hormones ceases. However, estrogen 
continues to be converted from androgen (produced by the adrenal glands) by aromatase 
in mammary adipose (117), which can cause high estrogen levels locally (118).  This 
biological pathway served as the basis for the development of an aromatase inhibitor 
class of compounds.  Current AI therapy includes usage of third-generation non-steroidal 
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 AIs such as anastrozole, letrozole, and exemestane. These AIs have been widely used in 
the treatment of advanced breast cancer in postmenopausal women with disease 
progression following tamoxifen therapy.  AIs have also been proposed as as first-line 
treatment for advanced disease, and eventually adjuvant therapy.  More data on the 
efficacy of fulvestrant after AIs is essential to determine the most appropriate sequence.  
 
Hormone-resistant Breast Cancer Therapy 
 Overexpression of many growth factor receptors, as well as growth factors, has 
been shown to confer varying degrees of estrogen-independent growth on ER-positive 
breast cancer cells.  The majority of hormone-resistant breast cancers maintain ERα 
expression, although ERα expression may be lost due to progressive methylation and 
silencing of the ERα promoter region (119-122).    Epidermal growth factor receptor 
(EGFR) and erbB2 are increased in tamoxifen-resistant breast cancer cell lines (123).  
Herceptin, a monoclonal antibody specific for erbB2, a member of the EGFR-tyrosine 
kinase (EGFR-TK) family, has shown promising results in the treatment of women with 
metastatic breast cancer (124).  Breast cancer cells resistant to fulvestrant become ERα-
negative and upregulate alternative growth signals, including erbB2, Wnt/β-catenin, and 
EGFR pathways (125).  The EGFR-TK inhibitor ZD1839 (Iressa) is also an effective 
inhibitor of cell proliferation (126) and when used in combination with antiestrogens, has 
been shown to be more effective at inhibiting proliferation of breast carcinoma cell lines 
than either drug alone (127).  Although the concept of combination biologic/hormonal 
therapy is still in its infancy, the future of biological therapies and their potential role in 
extending the window of effective endocrine therapies will require a more complete 
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 understanding of the mechanisms by which breast cancer cells transition from estrogen-
dependent growth to hormone-independent growth.  Effective “management” of breast 
cancer will require drugs that can target each of these pathways and that are used in the 
order that follows the transition of breast cancer growth from one pathway to another. 
 
ERα-MEDIATED TRANSCRIPTION 
 The specific nuclear actions of estrogens are determined by the structure of the 
hormone, the subtype or isoform of the ER involved, the characteristics of the target gene 
promoter, and the balance of coactivators and corepressors that modulate the final 
transcriptional response to the complexes of estrogen and ER.  ER uses three distinct 
mechanisms to exert its effects on its target genes (Figure R4; (5)).  E2 can stimulate 
receptor binding to DNA at estrogen response elements (128).  Estrogen-occupied ERα 
can also be tethered to other transcription factors that bind their respective response 
elements, such as AP-1 sites for fos/jun heterodimers (129, 130), Sp1 (131, 132), NF-κB 
sites, and others (133).  ERα can also be activated via phophorylation by other growth 
signaling pathways, or can activate other pathways through growth-signaling crosstalk 
(134), acting in non-nuclear or non-genomic fashion. 
 
 
Ligand-Dependent Activation of ERα at Estrogen Response Elements 
 
ERα binds to estrogen-responsive elements (ERE) to initiate transcription or 
repression of estrogen target genes (135).  ERα and ERβ can bind an ERE as a 
homodimer or heterodimer (136), and both bind the same ERE sequence and exert 
transcriptional regulation through the ERE (16).  Direct nuclear interaction is achieved by 
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 recognition of the DNA estrogen-response elements by receptor zinc fingers.  Estrogen-
response elements are present in the regulatory regions of estrogen target genes and are 
responsible for confering estrogen regulation of genes.  Highly estrogen-responsive and 
perfectly palindromic sequences have been found in the African clawed frog Xenopus 
laevis genes encoding vitellogenin (137).  From these natural EREs, a minimal consensus 
sequence for EREs has been derived.  The perfect ERE sequence is a 13 bp perfect 
palindromic inverted repeat with a 3 bp spacing of variable bases contained within the 
regulatory regions of target genes:  GGTCAnnnTGACC (26, 138-140).  ERα recognizes 
this sequence with high affinity.  The receptor-DNA complex then interacts with basal 
transcription factors, coregulator proteins, and other transcription factors to ultimately 
regulate transcription of the target gene (138, 140, 141). 
 Only a small number of most estrogen-inducible genes contain perfect consensus 
EREs.  In most cases, variant ERE elements have been described.  Variant EREs or even 
half-EREs, often separated by many base pairs, can still confer estrogen responsiveness 
(142).  For instance, the sequence 5'GGTCAnnnTGGCC3', which differs from the 
consensus sequence by 1 bp, mediates the estrogen induction of the Bcl-xl gene (143).  
These variant sequences bind ERs with less affinity, depending on the flanking bases 
(144).  Even as such, both consensus and imperfect EREs within the promoters of the 
human genes pS2 (145), c-fos (146), c-myc (147), PR (148), vitellogenin (149), and 
cathepsin D (150), are all used as experimental read-outs of ERα-mediated transcription, 
either as gene promoters driving E2-induced reporter genes or as induction of the gene 
mRNA.   
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Figure R4.  Ligand-Dependent and Ligand-Independent Estrogen-Receptor Activation.   
The estrogen receptor can be activated by estrogen (left-hand panel) or independently of 
estrogen — for example, by growth factors that increase the activity of protein kinases that 
phosphorylate different sites on the receptor molecule. In this model (center panel), the 
unbound but activated receptor will then exert transcriptional effects. In the case of the 
nonnuclear estrogen-signaling pathway (right-hand panel), cell-membrane estrogen receptors 
are located in cell-membrane invaginations called caveolae. Their activity is linked to the 
mitogen-activated protein kinase pathway, resulting in a rapid, nonnuclear effect.  Adapted 
from Gruber et al.  NEJM 2002 (5). 
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  Using ChIP assays, ERα and several cofactors were shown to bind endogenous 
target genes in a cyclical manner (151, 152), establishing a kinetic model for 
transcriptional activation by ERα that integrates cofactor involvement and histone 
modification.  Further studies built on the cyclical model of transcriptional activation 
with a comprehensive analysis of the coordinated recruitment of up to 46 regulatory 
factors to the estrogen-responsive pS2 gene promoter (153).  By performing sequential 
immunoprecipitations that simultaneously measure occupancy of the promoter by several 
factors, termed re-ChIP, multiple transcriptional complexes were identified that 
assembled with ERα at an endogenous promoter. α-Amanitin-synchronized cells were 
used to measure multiple ERα cycles with a resolution of 1-min time intervals.  
Unliganded receptor also exhibits cyclical binding but with faster kinetics than shown by 
ligand-bound receptor (152), revealing the possibility that the frequency of receptor-
cofactor cycles on a promoter may provide yet another element of regulation.  The 
importance of time as a variable in receptor transactivation resulted in the introduction of 
the “transcriptional clock” concept (153).  Both nonproductive and transcriptionally 
productive cycles exist for ERα and cofactor occupancy (153).  The ERα-DNA 
transcriptional clock has been summarized in an animation (153).    
 A major discrepancy in the timing of receptor cycling has been noted between 
ChIP studies and studies performed using fluorescence recovery after photobleaching 
(FRAP).  The mobile nature of nuclear receptors, and of other transcriptional 
components, revealed by FRAP demonstrated rapid (within seconds) exchange with 
chromatin targets. These studies argued against the idea of stable association of 
transcriptional complexes with promoter elements (154-156).  Cycles measured by ChIP 
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 are on the order of 35 to 40 min (153), whereas receptor associates with DNA with a half-
life of seconds (152).  It appears that FRAP is best suited for providing spatial 
information of receptor mobility.  ChIP assays appear to capture the average receptor 
scenario at a given time, though dynamics may be considerably faster.  Recruitment of 
proteasome components, chromatin-remodeling complexes, and heat shock proteins 
appear to facilitate this rapid cycling (153).  ChIP is therefore best suited for measuring 
the percentage of promoter associated with a particular protein.   
 Although ligand is critical for establishing receptor-coregulator interactions, 
ligand is insufficient for maintaining stable interactions over time (153, 157).  There is an 
active process of complex disassembly and removal from the promoter, suggesting that 
receptor cycling at a promoter is a mechanism to constantly probe for changes in cellular 
hormone levels (151, 152, 158).  Based on these findings, it is possible that ligand-bound 
ERα is highly mobile, translocates rapidly, and cycles on and off promoters on the order 
of seconds.  Accumulation of receptors at responsive promoters may be progressively 
stabilized by successive recruitment of coactivators to the growing complex.   
  
ERα Signaling Through Growth Factor Crosstalk Pathways  
 The underlying complexity of signaling cascades lies in the network of 
intracellular proteins that sequentially link a cell surface receptor to a nuclear 
transcriptional regulator.  ERα can signal through epidermal growth factor receptor 
(EGFR), analogous to the dependence of a wide variety of G-protein-coupled receptors 
on the EGF receptor to effect signaling (159).  Activated EGFR and other growth factors 
further stimulate MAPK and other kinase pathways resulting in additional cell response 
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 (160).  Studies using the cell-impermeable BSA-conjugated-17β-estradiol reveal estrogen 
activation of MAPK through membrane-bound ERs (161) and accumulation of second 
messenger molecules.  E2-binding can also directly influence non-genomic receptor 
activity by inducing receptor phosphorylation, which can, in turn, activate other growth 
signaling pathways.  Steroid-independent phosphorylation of ERα by HER-2 ligands can 
also promote cell proliferation (162).   
 
Coactivators 
 The transcriptional activity of ERα is regulated by coactivators, corepressors, and 
chromatin remodeling complexes.  By definition, coactivators are considered to interact 
directly with the steroid receptor and enhance transcription (163).  A concise list of all 
ERα interacting proteins are listed on the Human Reference Protein Database 
(http://hprd.org/interactions?protein=00589&isoform_id=00589_1&isoform_name=).  A 
summary of coactivators recruited to ERα and DNA in the presence of E2 have also been 
diagrammed and described using ChIP and FRAP technology (152, 153).  ERα interacts 
with the TATA-box–binding protein and RNA polymerase II, along with numerous 
nuclear-receptor coregulatory proteins to form a transcription initiation complex (5); the 
complexity of proteins provides increased stability and transcriptional specificity.  In 
response to E2 binding, residues of helix 12 within the ERα ligand binding domain 
interact with the LXXLL motif (NR-box motif), which is present in many nuclear 
receptor coactivators (164).  ERα transcription is thereby enhanced by coactivators, 
namely the p160-family (SRC 1-3), SWI/SNF complexes, CREB-binding protein (CBP), 
p300/CBP-associated factor (pCAF), and TRAP/DRIP/SMCC (163).  The SRC family of 
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 proteins and p300/CBP appear to have the greatest capacity to increase the transcriptional 
activity of ER (165, 166).    
 The expression levels of ERα and many coactivators are significantly higher in 
intraductal carcinomas than those in normal breast tissue (167).  The p160 coactivator 
AIB1 (Amplified In Breast cancer 1, or SRC3) is frequently amplified in breast tumors 
and correlates with ERα and PR expression, tumor size, (168), and tamoxifen resistance 
(169).  AIB1 is also is necessary and sufficient to induce E2-mediated receptor turnover 
(170), revealing a dual role for AIB1 in activating receptor transcription and facilitating 
receptor turnover.  Cyclin D1, which is frequently amplified in breast cancer, directly 
binds with ERα in a CDK-independent manner (171) and serves as a bridging factor 
between ERα and SRCs, providing an indirect mechanism to regulate breast cancer 
cellular growth (172). 
 Regulation of ERα gene expression involves complex interactions with many 
coregulators.  Coactivators use a variety of mechanisms to enhance ERα-mediated 
transcription.  Among them, SRC1 possesses HAT activity as well as transcription factor 
acetyl transferase activity (FAT) (173).  Multiprotein coactivator-containing complexes 
often contain CARM1, which has histone methyl-transferase (HMT) activity (174).  The 
SWI/SNF coactivator has ATPase activity and can alter DNA nucleosome arrangement 
by physically open the repressive chromatin structure to allow easier access to DNA 
(175).  The coactivator p300 serves multiple functions, including a bridge and scaffold 
for further coactivator recruitment, as a HAT to acetylate histone tails of nucleosomes, 
thus favoring chromatin remodeling and activation of basal-and enhancer-regulated 
transcription (176).  ERα acetylation at lysines K266/268 are also mediated by p300 (30).   
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  Several observations have been made that associate proteasome activity with ERα 
transactivation.  Several ERα coregulatory proteins are also components of the 
ubiquitin/proteasome degradation pathway. These are SUG1/TRIP1 (177), RSP5/RPF1 
(178, 179), E6-AP (180), and Ubc9 (181).  RSP5 and E6-AP are both ubiquitin ligase 
proteins and stimulate receptor-dependent gene activation (180).  In addition to 
proteasome-mediated degradation of ERα , other cofactors (SRC-1, TIFII, RAC3 and 
CBP) that associate with ERα are also degraded through proteasome action (182).  Oddly, 
E6-AP ubiquitin ligase activity is not required for its coactivator function, suggesting that 
E6-AP may serve to recruit proteasome components to clear transcriptional complexes, 
and not necessarily be involved in degradation of ERα (180).  The SUMO ligases PIAS1 
and PIAS3 also serve as receptor coactivators (32) by sumoylation of ERα at lysines 
K266/268.  Sumoylation enhances receptor transcriptional activity, suggesting that 
sumoylation directly or indirectly activates transcription.  Either sumoylation itself is an 
activator of receptor transcription, or alternatively, sumoylation blocks further receptor 
modification (by acetylation or ubiquitination), and thereby functions indirectly to 
maintain receptor transcriptional competency.  
    
 Another association is revealed in studies that showed the proteasome inhibitors 
MG132 and lactacystin abrogated transactivation by ERα (182), implying that 
proteasome degradation is necessary for ERα-mediated transcription.  However, more 
recent evidence indicates that proteasome inhibition by MG132 treatment prolongs ERα 
transactivation; despite receptor ubiquitination, degradation is not required for receptor 
transactivation, and ubiquitinated receptors remain transcriptionally active (183).  FRAP 
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 assays demonstrates that, in contrast to unliganded ERα which is highly mobile, the 
mobility of ERα is severely impaired by treatment with MG132 (155).  Immobilized 
receptors may therefore retain transcriptional activity, and receptor degradation may 
facilitate promoter clearance and thereby temporally limit receptor transactivation (184). 
 
Corepressors  
 Corepressors decrease receptor-mediated transcription by interacting with DNA-
bound receptors.  Corepressors recruit a complex of proteins having histone deaceylase 
(HDAC) activity in order to condense chromatin and silence gene expression (163).  
OHT antagonizes receptor transactivation by repositioning ERα helix 12 in a 
conformation that blocks coactivator recruitment (35).  ERα activity is also decreased by 
the recruitment of corepressors, including NCoR, to the ERα-ERE complex.  NCoR 
associates with the receptor as part of a complex that contains Sin3 and histone 
deacetylase (HDAC) complexes (185, 186). This NCoR-associated complex is 
responsible for histone modification and transcriptional silencing.  REA (Repressor of 
Estrogen Action) (187) and SMRT (Silencing Mediator for Retinoid and Thyroid 
hormone receptor) (188) function in similar manners also recruit HDACs.  NCoR is 
required for the antagonist activity of OHT; low tumor expression of NCoR has been 
associated with poor response to OHT (189).  TAF-1β differs from NCoR1 in that, rather 
than relying on the activities of its associated proteins, TAF-1β itself is able to repress 
histone acetylation (190). 
 The ubiquitin-like NEDD8 (Neural precursor cell Expressed, Developmentally 
Down-regulated 8), is also linked to ERα transcription (191, 192).  The NEDD8-
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 activating function of Uba3 is required for Uba3-mediated repression of ER 
transactivation.  Fan et al. later showed that Uba3-mediated inhibition of ERα 
transactivation function is due to increased receptor protein turnover (192).  Loss of Uba3 
neddylation activity resulted in a loss of ICI-induced receptor turnover.  As neddylation 
has only been shown to occur on the cullin family of proteins, the NEDD8 pathway likely 
stimulate ERα ubiquitination and degradation through neddylation of a cullin within an 
SCF-based E3-ubiquitin ligase complex, thereby activation the E3 ubiquitin ligase (192).   
  
ASPECTS OF ESTROGEN RECEPTOR REGULATION  
Receptor synthesis 
 ERα regulation is a key component of normal cell function.  ERα-mediated 
transcription is coupled to receptor and ERα mRNA downregulation in a classic 
autoregulatory negative-feedback manner (193-202).  The degree of cellular response to 
hormones is dictated by the level of ERα expressed in these cells (183, 203-205).  The 
cellular response to E2 is also due in part to distinct expression profiles of ERα in 
individual tissues (205).  Regulation of cellular ERα levels is therefore crucial to 
maintenance of normal cell function, and aberrant ERα signaling is a driving force in the 
development and progression of breast and other estrogen-responsive cancers (206, 207).   
 Regulation of ERα synthesis occurs at several levels.  E2 can upregulate and 
downregulate ERα mRNA expression level, depending on the tissue type (199, 208-210), 
allowing for regulation of ERα protein levels at the level of mRNA synthesis.  Additional 
mRNA regulation occurs at the level of mRNA stability.  The 3' UTR of ERα is 
unusually long, having twice the length (4.3 kb) of the coding region (2 kb).  Some 
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 regions of the 3’ UTR show extensive homology between species, including regions rich 
in AUUUA sequences, known to destabilize mRNA (211-213). The 3' untranslated 
region of the human ERα gene post-transcriptionally reduces mRNA levels (214) and 
mediates rapid messenger ribonucleic acid turnover (213).  Specific segments of the ERα 
3' UTR were later shown to be responsible for the destabilization of ERα mRNA (215).  
Utilizing miRNA microarray technology, a number of miRNA have been shown to be 
differentially expressed in breast cancer tissues.  Some miRNAs are up-regulated in 
breast cancer vs. normal breast tissue, and a smaller cohort of miRNAs is up-regulated in 
ERα-negative vs. ERα-positive tumors (216).  miR-206, which is elevated in ERα-
negative breast cancer downregulates the expression of ERα by binding two sites in the 
ERα mRNA 3' UTR (216), revealing a novel mechanism for the posttranscriptional 
regulation of ERα.   
Post-translational Modification  
Regulation of ERα protein stability and activity is mediated in part by a number 
of post-translational modifications.  ERα is covalently modified by phosphorylation, 
acetylation, ubiquitinylation, and sumoylation, providing a rheostat system in which to 
switch ERα protein between different functional states (217).  ERα is phosphorylated at 
serine, threonine and tyrosine residues (reviewed in (218)).  A threonine residue has also 
been shown to be modified by O-linked N-acetylglucosamine (O-GlcNAc) (219).  The ε-
amino group of lysine residues are substrates for acetylation, neddylation, sumoylation, 
methylation, and ubiqutination (220), although ERα has only been shown to be targeted 
for acetylation (30, 31, 221), ubiquitination (222), and sumoylation (32). A cysteine 
residue of ERα has been shown to be palmitoylated, anchoring ERα to the plasma 
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 membrane (52), allowing for rapid E2 signaling at the cell membrane.  Different 
modifications are mutually exclusive, thus leading to their potential competition.  
Competition exists between sites and further complicates the role of post-translational 
modification on receptor function (33, 220).   Competition between post-translational 
modifications at receptor residues is likely to occur, further modulating receptor protein 
function or stability (223-225).  The growing list of ERα post-translational modifications 
have been annotated on the Human Protein Reference Database 
http://hprd.org/interactions?protein=00589&isoform_id=00589_1&isoform_name=).   
 
Phosphorylation 
Steroid receptor phosphorylation has been the longest studied receptor 
modification, and a wealth of literature reviews are available (141, 218, 226).  All steroid 
receptors, including ERα, are phosphorylated after binding to their respective ligands 
(141), and in response to growth factors or cytokines (160, 227-229).  Depending on the 
ERα residue that is phosphorylated, as well as the kinase pathway that mediates receptor 
modification, phosphorylation can either increase or decrease receptor transcriptional 
activity and/or regulate receptor stability (230).  The role of phosphorylation in regulating 
receptor stability is detailed in the signals for receptor ubiquitination section.   
S118, and less so S104 and S106 are the main residues modified after ligand 
binding, resulting in enhanced E2-mediated transactivation (231-234).  S104 and S106 
are targets of cyclin A2-CDK2 (235).  S118, and also S167, are phosphorylated through 
MAPK pathway and CDK7 (228, 236).  Activation of the Akt pathway also stimulates 
S167 phosphorylation (237), increasing  the binding affinity of liganded ERα to an ERE 
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 (229).  S305 phosphorylation has been shown to block K303 acetylation and mutation of 
S305 resulted in a receptor that mimics the ERα-K303R hypersensitive phenotype (33).  
ERα dimerization and DNA binding are both enhanced when phosphorylation occurs at 
S236 (protein kinase A-mediated) (236, 238) or at Y537 (p60c-src/p56lck-mediated) 
(239, 240).  Both S118 and S167 phosphorylation have been suggested as positive 
markers for responsiveness to endocrine therapy in breast tumors, presumably as 
phosphorylation at these sites signifies that ERα pathways are being activated (241, 242).  
A recent paper has reported that constitutive phosphorylation of S118 may be responsible 
for protecting ERα from proteasomal degradation during chronic estrogen exposure 
(243). 
  
Acetylation 
 The role of acetylation in steroid receptor function has only recently been 
appreciated.  Similar to phosphorylation, ERα acetylation regulates receptor 
transcriptional activity (244).  Acetylation of lysine residues neutralizes the positive 
charge on the lysine residue, effectively modifying receptor-DNA and receptor-protein 
interactions.  The cofactor p300 but not P/CAF, both of which have intrinsic acetylase 
activity, was found to directly acetylate lysine residues at position 302/303 at the 
boundary between the hinge region and the LBD (31).  Mutagenesis of these residues to 
either neutral (K to A, Q or T) or to arginine (R), in the presence of exogenous p300, 
resulted in an increased E2-induced transactivation capacity of the mutant ERα (31), 
suggesting that ERα acetylation may be one mechanism by which receptor sensitivity to 
hormone is to decreased (31).  Furthermore, it has been suggested that ERα is unable to 
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 be acetylated due to mutation, transcription may be potentiated by an increase in the time 
that transcriptionally competent ERα resides on a responsive promoter, allowing further 
increase in receptor transactivation (190) .  One study has shown that over 30% of the 
premalignant breast tumors posses an ERα mutant in which a somatic DNA mutation 
resulted in a K303R mutated receptor (245) that was hypersensitive to E2 and enhanced 
breast cancer cell proliferation due to increased affinity for the coactivator TIF2 (245).  
Loss of this specific acetylation site was suggested as one possible mechanism that 
promotes or accelerates the development of cancer from premalignant breast lesions.  
Several studies dispute the relative frequency of the mutation in US population-based 
studies (246, 247), and the mutation was not detected in a cohort of Japanese breast 
cancer samples (248).  A more precise estimation of K303R mutation in breast cancer has 
yet to be determined, although small sampling size in the initial report may have 
overestimated the frequency in breast hyperplasias examined.   
 Contrary to original reports that placed ERα acetylation at K302/303, Kim et al.  
has reported that ERα is acetylated by p300 at lysines 266/ 268 (30).  Acetylation of 
K266 and K268 stimulated ligand-dependent activity in reporter gene assays (30).  The 
seemingly opposing actions of acetylation, enhancing transactivation but reducing E2 
sensitivity, may be resolved if acetylation is thought of as fine-tuning mechanism for 
ERα activity.  Acetylation may enhance E2-induced transcriptional activity while 
simultaneously decreasing receptor sensitivity to ligand, providing an immediate positive 
response to ligand while dampening prolonged E2 stimulation.  PKA-mediated 
phosphorylation of ERα S305 has been shown to prevent K303 acetylation, suggesting 
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 that kinase-activation of ERα limits acetylation-activation and prevents overstimulation 
through dual post-translational modification (33). 
  The acetylation of ERalpha by p300 is reversed by native cellular deacetylases, 
including trichostatin A-sensitive enzymes (i.e. class I and II deacetylases) and 
nicotinamide adenine dinucleotide-dependent/nicotinamide-sensitive enzymes (i.e. class 
III deacetylases, such as sirtuin 1) (30).  Template-activating factor β (TAF1β) also 
inhibits ERα acetylation and subsequent transactivation by blocking receptor acetylation 
or by increasing non-acetylated ERα interaction with responsive promoters (190).  pp32 
has also been shown to block receptor acetylation, in part by promoting apo-ERα binding 
to DNA, and elevating non-productive receptor-promoter cycling (190, 249).  In addition 
to receptor acetylation, numerous ERα-interacting proteins are acetylated, further 
complicating the role of acetylation in ERα function (reviewed in (250)). 
 
Sumoylation 
 Sumo is structurally related to ubiquitin (251), though its attachment is typically 
monomeric.  Sumoylation does not trigger protein degradation (251); rather, it alters 
several different protein functions including subcellular localization, DNA-binding, and 
transcriptional regulation (252).  Similarly to ubiquitinylation, sumoylation is a three-step 
process involving an E1 activating-enzyme (Aos/Uba2), an E2 conjugation enzyme 
(Ubc9) and an E3 ligase belonging to one of three classes (253).  Sumo is covalently 
attached to target protein lysines residues embedded in the consensus ψKxE motif, where 
ψ is a large hydrophobic residue (I, V, or L), K is the lysine to which sumo is conjugated, 
X is any amino acid, and E is glutamic acid {Sampson, 2001 #3637}.  Although ERα 
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 does not have the consensus ψKxE motif, it is still sumoylated by the E3 ligases PIAS1 
and PIAS3 (32). ERα has been shown to be sumoylated in the receptor hinge region, at 
K266 and K268 and possibly K299, K302, and K303.  Sumoylation is strictly ligand-
dependent (32).  Together with Ubc9, PIAS1/3 act as ERα coactivators, however this role 
is independent of their enzymatic activity (32, 254).   Elimination of the sumo acceptor 
sites leads to reduced ERα activity (32), although the exact role sumo plays in this is 
obscured by the fact that ERα is also acetylated at K266 and K268 (30).  Competition 
may therefore exist between receptor acetylation and sumoylation.  Both acetylation and 
sumoylation are reversible modifications.  Several SUMO-specific proteases have been 
discovered and reverts target proteins to their unmodified state (255); dynamic 
interchange of ERα post-translational modifications may add another dimension of 
receptor regulation precision.   
 
Neddylation  
 NEDD8, also an ubiquitin-like protein (256) , is conjugated (neddylation) in a 
similar manner as ubiquitination, and involves the action of amyloid precursor protein-
binding protein (APP-BP1)/Uba3, a heterodimeric E1-like enzyme, and Ubc12, an E2-
like enzyme (257).  Whether a ligase is required for neddylation is unknown. To date, the 
only established function of Uba3 is to activate NEDD8, which is required for 
neddylation of cullin family members (258, 259).  Cullins are essential components of the 
SCF (Skp1-cullin-F-box protein) group of E3 ubiquitin ligases (260-262).  Cullin 
neddylation plays a crucial role in stimulating the ligase activity of cullin-based ubiquitin 
ligase complexes (192, 256, 263-265).  Regulation of cullin-based ligase activity by Uba3 
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 is the limiting factor in neddylation-associated suppression of receptor activity (191), and 
is required for the recruitment of a SCF E3 ligase complex to ERα in the presence of ICI 
(192).  Functional neddylation activity of Uba3 is therefore required for ICI-induced 
degradation of ERα and is essential for the antiproliferative activity of ICI (192).  
Downregulation of NEDD8 pathway components may be one mechanism for ERα-
positive breast cancers to become resistant to ICI (192).  Direct neddylation of steroid 
receptors has not been shown. 
 
DISSECTION OF ESTROGEN RECEPTOR DEGRADATION PATHWAYS 
 
 The selective degradation of many short-lived proteins in eukaryotic cells is 
carried out by the ubiquitin-proteasome pathway.  Proteins are targeted for degradation 
by covalent ligation to ubiquitin, a highly conserved 76 amino-acid residue protein.  
Ubiquitin was first discovered in 1975 (266), with subsequent discovery of the multi-step 
ubiquitin activation (E1), conjugation (E2) and ligation (E3) enzyme system (267) 
(reviewed in (268)).  Ubiquitin-mediated degradation of regulatory proteins plays 
important roles in the control of numerous processes, including cell-cycle progression, 
signal transduction, transcriptional regulation, receptor down-regulation, and endocytosis, 
immune response, development, and apoptosis.  Abnormalities in ubiquitin-mediated 
processes have been shown to cause pathological conditions, including Alzheimer’s 
disease and cancer (268).  It is worth noting that Aaron Ciechanover, Avram Hershko and 
Irwin Rose were awarded the Nobel Prize for Chemistry in 2004 for their the pioneering 
discoveries that describe the ubiquitin-proteasome pathway.   
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E1-E2-E3 ubiquitin attachment 
 The 76 ubiquitin protein is covalently linked to proteins targeted for degradation, 
marking them for recognition by the 26S proteasome (269, 270).  Ubiquitin protein 
ligation requires the sequential action of at least three enzymes. Usually there is a single 
E1, but there are many species of E2s and multiple families of E3s or E3 multiprotein 
complexes.  Extensive homology exists between ubiquitin and ubiquitin-like proteins 
such as NEDD8, RUB1, and SUMO.  Activation and conjugation of these homologous 
proteins follow similar E1-E2-E3 pathways (reviewed in (218)).  Ubiquitin is activated 
by conjugation to the ubiquitin activating enzyme (E1 or Uba).  The activated ubiquitin is 
subsequently transferred to a ubiquitin-conjugating enzyme (E2 or Ubc).  The E2 proteins 
catalyze substrate ubiquitination in conjunction with an ubiquitin-protein ligase (E3 or 
Ubl).  E3s are enzymes that bind, directly or indirectly, to specific protein substrates and 
promotes the transfer of ubiquitin to an ε-amino group of a substrate protein lysine 
residue (Figure R5). 
 
 
E3 ubiquitin ligases can be classified into three major structurally distinct types: N-end 
rule E3s, E3s containing the HECT (Homology to E6-AP C-Terminus) domain, and E3s 
with the RING (Really Interesting New Gene) finger, including its derivatives, the U-box 
and the PHD (reviewed in (271)).   The HECT domain family includes E6-AP (E6-
associated protein), and is responsible for the ubiquitinylation and degradation of p53 
(272) and is a coactivator for ERα (180).   Most HECT-domain proteins are likely E3 
enzymes or parts of multiprotein complexes that contain E3-like activities.  The RING 
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Figure R5. Outline of the Ubiquitin-Conjugation Pathway   Activation of the ubiquitin C-
terminus by E1 proceeds in two steps: adenylation (not shown) followed by attack by a 
cysteine side chain to form a thioester bond between the E1 and ubiquitin. Ubiquitin is then 
passed to a cysteine of an E2. Ligation of the ubiquitin to a substrate (S) follows either 
directly with the aid of a RING-bearing E3 or after an intermediate transthiolation to a 
cysteine side chain of a HECT-domain E3. Both types of E3 interact with their substrates, 
many of which acquire a polyubiquitin chain rather than just a single ubiquitin.   Adapted 
from Hochstrasser  et al. Cell 2006 (3). 
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 finger domain binds two zinc atoms using pairs of cysteine residues, creating a cross-
braced finger-like structure (273).  The PHD (plant homeodomain) and U-box E3s are 
related to RING finger E3s in that the PHD domain is a variant of the RING finger, 
whereas U-box E3s adopt a RING structure, but lack conserved Zn-coordinating residues, 
(274).  The U-box E3 ligase CHIP promotes ERα turnover (275, 276), and is discussed in 
detail in the ERα basal turnover section.  RING E3s ubiquitin ligases comprise a 
heterotetrameric group of proteins consisting of Skp1-Cullin-RING-F-box (SCF) protein 
complex (256, 277).  Together, these proteins coordinate the RING E3-mediated transfer 
of ubiquitin from the E2 to the protein target, utilizing the F-box as a substrate specificity 
recognition molecule (256).   
 After the linkage of ubiquitin to the substrate protein, a polyubiquitin chain is 
usually formed, in which the C-terminus of each ubiquitin unit is ligated to the previous 
ubiquitin.  Synthesis of long ubiquitin chains is mediated by E3 ligases and in some cases 
by additional polyubiquitin ligases called E4s (278).   p300 contains E4-like activity and 
facilitates polyubiquitination of p53 following MDM2-mediated monoubiquitination 
(279).  It remains unknown whether p300, as an ERα coactivator, is involved in receptor 
polyubiquitination.   
 
The 26S Proteasome 
 Proteins ligated to polyubiquitin chains are degraded by the ~1500kDa 26S 
proteasome complex (reviewed in (269).  The 26S generates peptide fragments and free 
amino acids through the use of three distinct proteolytic activities: trypsin-like, 
chymotrypsin-like, and post-glutamyl peptidyl hydrolytic (PGPH) activities (280).  The 
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 19S subunits act as caps at the entry and exit sites for the 26S proteasome (Figure R6).  
These caps recognize ubiquitinated proteins and contain enzymes that depolymerize the 
ubiquitin chain and as well as enzymes to unfold the substrate and facilitate its entry into 
the 20S particle (281).  The 19S subunit also isolates the active sites within the 20S 
particle, restricting substrate entry and delaying or preventing nonspecific destruction of 
cytosolic proteins.  One regulatory protein component of the 19S subunit, SUG1, 
interacts directly with ERα and stimulates receptor ubiquitination and turnover (282), 
providing a direct link between ERα and the proteasome.  
 
Ubiquitin-C-Terminal Hydrolases and Isopeptidases 
 
The uniqueness of ubiquitin and its ability to direct protein function and 
degradation necessitates mechanisms that guarantee its efficiency and allow for ubiquitin 
removal if needed.  Many deubiquitinating enzymes (DUBs) exist, suggesting this large 
number of hydrolases allow for specific functions, such as the recognition of different 
types of ubiquitin conjugates, or as as proof-reading enzymes, altering the rate of mono-
or-polyubiquitination and allowing for reversal of protein fate at various stages of the 
process (283).  DUBs are classed into two distinct families: ubiquitin C-terminal 
hydrolases (UCHs) and the ubiquitin-specific proteases (USPs/UBPs). UCHs are 
relatively small enzymes (20-30 kDa) that catalyze the removal of peptides and small 
molecules from the C-terminus of ubiquitin.  Most UCHs cannot generate monomeric 
ubiquitin from protein conjugates or disassemble poly-ubiquitin chains. USPs can process 
ubiquitin precursors, remove ubiquitin from protein conjugates and disassemble ubiquitin 
chains.  Most recently the JAMM isopeptidases, otubains and ataxin-3/josephin have also 
been identified as ubiquitin-specific proteases (268).  Proteases also exist for ubiquitin-
50
Figure R6.  The 26S proteasome.  The 26S proteasome is composed of a 20S core 
proteasome subunit and is capped on each end by a 19S regulatory subunit.  The ATP-
dependent protease domains are contained within the 20S core.  The 19S subunits perform 
regulatory functions, recognizing ubiquitinated proteins and facilitating protein unfolding and 
proteasomal entry.  Image of the proteasome courtesy of Stockholm University, Department 
of Molecular Biology and Functional Genomics (http://www.molbio.su.se./) 
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 like proteins:  SUMO-specific proteases (SENPs) (255), NEDD8-specific proteases 
(NEDP1, COP9 signalosome) (284) and ISG15-specific proteases (UBP43) (285); 
common regulatory mechanisms may therefore exist between ubiquitin and ubiquitin-like 
pathways.  DUB-mediated ubiquitin hydrolysis of ERα lysines remains an unexplored 
field. 
 
Inhibitors   
Specific inhibitors of the proteasome have proved to be important research tools, 
allowing dissection of the structure and function of the proteasome as well as elucidating 
the ERα degradation pathways that converge on the 26S proteasome.  Peptide-aldehyde 
inhibitors, including Cbz-leu-leu-leucinal (MG132) are potent inhibitors of the 
chymotrypsin-like activity of the proteasome, while lactacystin strongly inhibits both 
trypsin- and chymotrypsin-like activities of the complex (286).  A recently developed 
derivative of the calpain inhibitors, carboxybenzyl-Leu-Leu-Leu-vinyl sulfone (Z-L3VS) 
inhibits efficiently and specifically all three activities of the proteasome (287).  These 
inhibitors are eliciting appreciable interest because of their potential applications in 
medicine, especially in cancer therapy.  Bortezomib (originally PS-341 and marketed as 
Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to 
be tested in humans (288). It is approved in the U.S. for treating relapsed multiple 
myeloma and mantle cell lymphoma.  Systemic proteasome inhibition was anticipated to 
be quite toxic, but Bortezomib has only been limited by increased peripheral neuropathy 
and myelosuppression in patients. The ability of these inhibitors to induce apoptosis 
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 without severe side effects is likely due to the apparent selectivity towards rapidly 
dividing, transformed cells (289).   
 
DISTINCT ERα DEGRADATION PATHWAYS 
 Distinct mechanisms that convey proteins to the proteasome, including 
ubiquitination and neddylation, have been identified as key regulatory processes involved 
in ERα turnover (218).  Receptor levels are maintained by distinct degradation pathways 
that ultimately converge on the ubiquitin-proteasome pathway (182, 192, 205, 290-295).  
The engagement of one pathway over another depends on the nature of the stimulus (155, 
230, 293, 294).  The protein partners, pathways, and the potential roles of ERα lysines 
302/303 in ERα turnover has been summarized in a model (Figure 9).  Although 
seemingly energy wasteful, receptor turnover allows for precise control over receptor-
mediated transcription, as the overall magnitude of response to estrogen is dependent on 
the cellular level of ERα (128, 203, 205).  All steroid receptors are subjected to 
ubiquitination, and several of the enzymes involved in receptor ubiquitination have been 
identified. In most cases however, the exact site of modification has proven difficult to 
identify, due to the instability, low-abundance, and relative insolubility of 
polyubiquitinated proteins.   
 The decline in receptor number is clearly part of an adaptive response that allows 
cells to alter sensitivity to external stimuli depending on environmental conditions.  The 
mechanisms responsible for partitioning receptors between these pathways are yet to be 
elucidated, but tilts in this balance have the potential to alter the availability of functional 
receptors. 
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Proteolysis of unliganded receptor 
In the absence of ligand, ERα is a short-lived protein (half-life of 4-5 hours) and 
undergoes constant degradation (296).  ERα folding involves progressive dynamic 
association with folding machinery, heat shock proteins, and chaperones in a 
“foldosome” (297).  Through this network, ERα is either processed forward into 
transcriptionally competent protein or regressed and targeted for degradation.  ERα must 
be protected during the folding process to mask the DNA-binding domain of the receptor, 
shield the hydrophobic ligand binding pocket, and reduce unliganded receptor activity 
(298, 299).  An equilibrium exists between proteasome-mediated receptor degradation 
and heat shock proteins (hsp)-mediated receptor folding (300).  Receptors associate 
dynamically with the foldosome, and through cycles of hsp binding and release, ERα is 
able to adopt a native conformation and achieve ligand binding competency (301).  
Progression through the foldosome requires ATP hydrolysis mediated by ATPase activity 
of Hsps and other foldosome components (297).  During each of the release or ATP-ADP 
exchange states, receptors are vulnerable to potential degradation as misfolded proteins. 
ER is progressively transferred from hsp40 to hsp70 and associated cochaperones Hsc-
70-interacting protein (Hip) and Hsp organizing protein (Hop).  The U-box E3-ubiquitin 
ligase CHIP (Carboxy-terminus of Hsc-70-Interacting Protein) is recruited to the 
Hsp90/Hsc70 complex and is responsible for basal and geldanamycin (GA)-induced 
receptor ubiquitination (275, 276).  CHIP antagonizes receptor maturation by binding to 
hsp90 through a tetratricopeptide repeat domain and therefore competitively inhibits the 
binding of other tetratricopeptide repeat-containing cochaperones such as Hop and p23 
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 (302).  In disrupting hsp90 interactions with cochaperones, CHIP effectively alters the 
composition of the chaperone complex.   The cochaperone Bag1 is found in early 
receptor-chaperone complexes and has been shown to link Hsp70 client proteins to the 
proteasome through its N-terminal ubiquitin-like domain (303, 304).  Bag1 may therefore 
escort hsp70 client proteins within proximity of the proteasome and, through induction of 
nucleotide exchange, release substrate directly to the 26S proteasome for degradation 
(305).  Bag1 interacts with many steroid hormone receptors, including the androgen 
(306), estrogen (276), glucocorticoid (307) and retinoic acid receptors (308).  Both CHIP 
and Bag1 have been copurified with the unliganded ERα along with hsp 40, hsp70, hsc70, 
and hsp90 (275, 276).  CHIP has also been found to interact directly with Bag1 (309), 
suggesting that CHIP and Bag1 may cooperate to increase the turnover rate of the 
unliganded ERα, by increasing receptor ubiquitination and proteasome delivery (275).  
Protein synthesis inhibitors cycloheximide and puromycin do not affect the turnover rate 
of unliganded ERα, revealing that all cochaperone proteins that mediate apo-receptor 
turnover are present in breast cancer cells (294).  Hsp90 inhibitors such as GA  (275) and 
ritonavir (310) enhance apo-ERα turnover.  The GA analog 17-allylaminogeldanamycin 
(17-AAG) has been proposed as chemotherapy in a variety of pathologies including 
breast cancer, and as such, is currently in phase I clinical trials (311). 
 
Ligand-induced ERα degradation 
 Downregulation of receptor in response to ligand was one of the earliest 
functional readouts of steroid hormone action (1, 312).  Proteasome-mediated ligand-
induced downregulation is highly conserved among most nuclear receptors, including 
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 ERα (290-292), PR (313), GR (314), TR (315), RAR (522), RXR (316), MR (317), and 
PPAR (318), although downregulation in response to ligand is not a generalized response 
among nuclear receptors since AR (319) and VDR are upregulated by ligand (320).  E2-
induced receptor degradation is coupled with transcription and requires new protein 
synthesis (155, 170, 182, 230, 293-295, 321), suggesting that synthesis of regulatory 
proteins, perhaps an E3 ligase or F-box protein, is required in order to initiate E2-induced 
turnover.  Contrary to breast cancer cells, CHX does not block E2-induced ERα turnover 
in PR1 pituitary lactotrope cells (290), revealing alternative and tissue-specific 
mechanisms for ligand-induced receptor turnover. 
 Upon ligand binding, ERα undergoes a conformational change that leads to the 
dissociation from a Hsp90-based complex and effectively completes the folding process 
(35).  ERα is then capable of dimerization and translocation to the nuclear compartment.  
Ligand-induced receptor disassociation from CHIP directs ERα toward alternative 
degradation pathways (275, 276, 293, 294, 322).  In the presence of ligand the turnover 
rate of ERα can be increased or decreased, depending upon the nature of the ligand, thus 
modulating receptor protein levels (155, 230, 293, 294).  ERα is preferentially 
ubiquitinated in the presence of E2 (222), and ICI (182, 291).  Agonists induce 
degradation with a potency that is directly related to their binding affinity, though the 
efficiency of degradation can vary (323).  Partial agonists, such as tamoxifen, and 
antagonists fail to or only weakly induce proteolysis thereby stabilizing ERα (323).  
Thyroid hormone and protein kinase K activators (Forskolin, 8-bromocAMP) also block 
receptor degradation and subsequently increase ERα protein levels (324-326).  
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 Proteasome-related Coactivators   
 Aside from receptor degradation, studies of nuclear receptors have revealed 
multiple points of overlap between the proteasome and receptors. Polyubiquitination and 
degradation of ERα and other nuclear receptors by the ubiquitin–proteasome system is 
important for regulating nuclear receptor levels and their transcriptional activities (152, 
182, 222, 276, 291). Several components of the ubiquitin-proteasome degradation system, 
such as PSMC5 (SUG/TRIP1) (177), RSP5/RPF1 (179), UBCH7 (327) and CHIP (275, 
276), have been reported to interact with a number of nuclear receptors, including ERα. 
Recently, sumoylation has been identified as another mechanism that regulates the 
transcriptional activity of ERα and involves UBC9, PIAS1 and PIAS3 (32, 254). 
 The E3 enzyme E6-AP, which has been implicated as the cause of Angelman 
syndrome (328, 329) is a coactivator for ERα (180) along with its conjugating enzyme 
UbcH7(327), and another E3 ligase mouse double minute 2 (MDM2) (330).  The stability 
of ERα is correlated with the ability of receptor to recruit these E3 ligases to target gene 
promoters; it appears these coactivators may facilitate stalled transcriptional complexes 
or removal of pre-initiation complexes thereby enhancing transcription (331).  UBCH7 
has been identified as a coactivator for several steroid hormone receptors, including ER, 
PR, AR, GR, and RAR (327), suggesting this mechanism may be conserved among 
nuclear receptors.  The ubiquitination of proteins by the E6-AP E3 enzyme depends on 
ubiquitin conjugation by UbcH7 (327), although interestingly, the ubiquitin ligase 
activity of E6-AP is not required for its ERα coactivator function (180).   
 Suppressor for Gal1 (SUG1), a subunit of the regulatory 19S cap of the 
proteasome, directly interacts with ERα and ERβ in a ligand-dependent manner and is 
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 recruited simultaneously with elongation factors to the pS2 promoter (152, 153, 332), 
suggesting the proteolytic component of the 26S proteasome may be recruited to remove 
stalled RNA polymerase II at the transcriptional stop sites terminating transcription (333).  
SUG1 stimulates receptor ubiquitination and turnover, thus impairing its transactivating 
potential (282).  
 
Signals for Receptor Ubiquitination 
 The ERα N-terminal B and C domains, as well as the C-terminal E domain are 
required for ligand-induced downregulation (182, 318, 331, 334).  These two regions 
encode the AF1 and AF2 domains, respectively, and neither is sufficient to induce 
turnover on its own.  Therefore, one model for signaling degradation might involve 
ligand-facilitated interactions between the AF1 and AF2 that when joined, create a 
binding surface for either a ligase or other accessory proteins that is recognized by the 
ubiquitination machinery.  Perhaps folding at the hinge-region exposes the hinge to such 
machinery.  Alternatively, AF1 and AF2 may serve distinct purposes, such as recognition 
vs. recruitment.  The overall implication of the dual requirement for B and E domains is 
that, unlike transcription where AF1 and ASF2 can function as independent modules, the 
signal(s) for ubiquitin/proteasome-mediated degradation are coordinated by distal regions 
of the receptor necessitating the full-length receptor.  Deletion of the last 61 amino acids 
of ERα, which includes helix 12 residues, abolishes ligand-mediated downregulation of 
the receptor, as do point mutations in the ligand binding domain that impair coactivator 
binding (182).  The truncated ERα mutant 1-282 does not contain the LBD/AF2 region 
and therefore is not degraded after E2 treatment, but is stabilized by MG132, suggesting 
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 that the AF1 domain contains lysine residues that may be ubiquitinated and facilitate 
unliganded receptor degradation (182). 
 Phosphorylation events, especially within PEST domains often trigger a given 
protein to be degraded by the ubiquitin-proteasome pathway (268, 335).  A PEST 
sequence exists in the carboxyl-terminal F domain of ERα (219, 336).  Although 
phosphorylation of the ERα PEST has not been shown, ERα from murine, bovine, and 
human sources are all modified by O-linked N-acetylglucosamine (O-GlcNAc) at Thr-
575 within the PEST sequence (219, 336).  The PEST sequence for ERα does not appear 
to regulate receptor turnover (43), and no data exists if O-GlcNAc modification alters 
receptor stability. 
 The primary target for ligand-induced phosphorylation of ERα is S118, and 
mutation of this site results in loss of ERα proteolysis, consistent with a possible role for 
phosphorylation in signaling receptor turnover (323) though later reports by the same 
group suggested this was not always the case (331).  Phosphorylation can either stabilize 
or destabilize ERα, depending on the kinase and the amino acid residue that is 
phosphorylated.  PKC and ERK7 destabilize ERα (230, 337), while PKA stabilizes ERα 
(230, 326).  Kinase inhibition has also been shown to prevent E2-induced down-
regulation of ERα (338), further suggesting that phosphorylation regulates ligand-induced 
receptor turnover.   
 BRCA1 mutations are a major contributor for familial breast cancer (339).  
BRCA1 is a DNA repair enzyme, and when complexed with BARD1, has ubiquitin 
ligase activity (340).  Recently, monoubiquitination of ERα K302 by BRCA1/BARD1 
was reported, and reduced receptor transcriptional activity (34).  BRCA1 interacts with 
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 RAP80, a deubiquitination enzyme (341), possibly revealing the first deubiquitination 
enzyme involved in ERα regulation. 
 
Antiestrogen-induced ERα Turnover 
  The SERD class of antiestrogens blocks ERα activity by inhibiting newly 
synthesized receptors from translocating to the nucleus, blocking receptor-coactivator 
interaction, and rapidly inducing polyubiquitination and downregulation (140, 155, 182, 
198, 230, 291, 342-344).  FRAP experiments reveal rapid ERα mobility in the absence of 
ligand, which is slowed by E2 and OHT, and completely immobilized by ICI (113-115, 
152, 155) by receptor sequestration in the nuclear matrix with cytokeratins 8 and 18 
(114).  Unlike E2-induced turnover, protein synthesis inhibitors (cycloheximide, 
puromycin) do not inhibit receptor downregulation by pure antiestrogens (292, 295, 345).   
 Full antagonists like ICI are potent receptor downregulators (323).  ICI is 
structurally a steroidal compound with an extremely long, flexible extending side chain.  
The current consensus among agonist and antagonist studies is that the degradation signal 
is in part conferred by the conformation of helix 12 in the ligand-binding domain.  Helix 
12 serves as a structural probe for ligand binding, and determines receptor fate (36, 346-
350).  The bulky ICI side-chain prevents helix 12 from closing over the ligand binding 
pocket resulting in exposure of hydrophobic residues that are normally packed inside the 
LBD and protected from the surrounding solvent.  Exposed hydrophobic patches on the 
protein surface are known targeting signals for protein degradation (351).  Further 
structural and molecular determinants for distinguishing SERM and SERD action  have 
been probed using derivatives of tamoxifen and ICI (352), revealing the requirement of 
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 hydrogen bonding between ligand functional groups and helix 12 to maintain helix 
positioning (352).  ERα-E542A, a helix 12 receptor mutant, is not degraded in the 
presence of E2 and has limited degradation in response to ICI 182,780 (349), likely due 
to loss of a hydrogen bonding residue.  Alternatively, as ERα, but not ERβ, is degraded in 
the presence of ICI (344), ligand binding pocket mutations may also alter ERα in a way 
that mimics the ERβ ligand-binding pocket.  The activating enzyme of NEDD8 (Uba3) 
inhibits steroid receptor function (191), and was later shown to be required for 
proteasome-mediated degradation of ERα and essential for the antiproliferative activity 
of ICI 182,780 in ERα-positive breast cancer cells (192) 
 
PROTAC:  Selective Enhancement of ER Degradation 
 E3 ubiquitin ligases and F-box proteins determine the specificity of proteasome-
mediated protein degradation.  Unfortunately in many cases, including ERα, the E3 or F-
box proteins for turnover are not known.  One clever remedy is to alter the tropism of a 
known E3-ligase away from its conventional target and towards a protein of interest.  
This approach has evolved into the development of a heterobifunctional small molecule 
called Protein Targeting Chimeric Molecules (PROTAC) that serves as a bridge to link a 
target protein to an ubiquitin ligase.  Such an approach was used to design an E3 ligase 
that targets ERα or AR (353) and other proteins of interest (354).  PROTACs have been 
developed using the the IκBα phosphopeptide linked to either estradiol (E2) or 
dihydroxytestosterone (DHT) and were used to to recruit ER or AR to the SCFß-TRCP 
complex to accelerate their ubiquitination and degradation (353).  This approach remains 
a promising method to direct receptor turnover in vitro.   
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Novel E3 ligases 
 Novel RING E3 ligases are being identified that are closely linked to human 
breast cancer and are coregulated with ERα.  BRCA1/BARD1 binds and 
monoubiquitinates the ERα hinge (34).  In apparent opposition, RAP80, which contains 
ubiquitin interacting motifs and binds the hinge-region of ERα (355) in a ligand-
dependent manner, reduces ERα ubiquitination and stabilizes the receptor.  RAP80 is also 
known to interact with BRCA1 (341).  The balance between BRCA1and RAP80 
interaction with ERα may be one mechanism that regulates the degree of receptor 
ubiquitination.  Perhaps inhibitors of RAP80 may enhance BRCA1-mediated ERα 
ubiquitination.  Similarly, knockdown of Siah2, an E3-ubiquitin ligase that degrades the 
corepressor NCoR (356) may also suppress ERα function.  Alternatively, upregulation or 
activation of estrogen-responsive E3 ligases E6-AP (180), Rsp5/Rpf1 (179), and EEP 
(357) may be useful methods for downregulating ERα. 
Although extensive research has gone into the discovery of ERα ubiquitination 
processes, little is known if/when ERα is deubiquitinated.  As inhibition of 
deubiquitination can promote proteolysis, discovery of a deubiquitin enzyme for ERα 
may lead to novel drug targets.  Inhibiting this enzyme would function similarly to a 
SERD drug.  Broad spectrum inhibitors of DUB enzymes exist, including N-ethyl 
maleimide (NEM), as well as aldehyde and vinyl sulfone derivatives of ubiquitin.  To 
date, these compounds have not been compared to current drugs that increase receptor 
ubiquitination.   
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  Continued investigation into the mechanisms by which ERα is degraded will 
bring a greater understanding to the role this receptor plays in breast cancer proliferation 
and cancer progression.  It is therefore not so much the endpoint as it is the process by 
which receptors are marked for proteolysis that will have the broadest impact on receptor 
activity.  Further evaluation of the sequence requirement for proteasome-mediated 
degradation of ERα may reveal post-translational modifications, cellular 
compartmentalization, DNA binding, or specific protein interactions, that may contribute 
to ERα fate.  The components of the ubiquitination machinery responsible for transferring 
ubiquitin to receptors are not definitively established, and it remains unknown which of 
the 29 receptor lysine residues are sites for ubiquitination.  Pinpointing the ubiquitinated 
residues may reveal novel receptor interacting proteins and may provide additional 
methods to repress ERα action in breast cancer. 
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REGULATION OF ERα UBIQUITINATION AND PROTEASOME-MEDIATED 
RECEPTOR DEGRADATION  
 
 
ABSTRACT 
 
Cellular levels of estrogen receptor-alpha (ERα) protein are regulated primarily by the 
ubiquitin-proteasome pathway.  Dynamic interactions between ERα and the protein 
degradation machinery facilitate the downregulation process by targeting receptor lysine 
residues for polyubiquitination. To date, the lysines that control receptor degradation 
have not been identified. Two receptor lysines, K302 and K303, located in the hinge-
region of ERα, serve multiple regulatory functions, and we examined whether these 
might also regulate receptor polyubiquitination, turnover, and receptor-protein 
interactions.  We utilized ERα-negative breast cancer C4-12 cells to generate cells stably 
expressing wild-type (wt) ERα or ERα with lysine-to-alanine substitutions at K302 and 
K303 (“ERα-AA”).  In the unliganded state, ERα-AA displayed rapid polyubiquitination 
and enhanced basal turnover, as compared to wtERα, due to its elevated association with 
the ubiquitin ligase CHIP and the proteasome-associated cochaperone Bag1.  Treatment 
of C4-12 cells with either 17β-estradiol (E2) or the pure anti-estrogen ICI 182,780 (ICI) 
induced rapid degradation of wtERα via the ubiquitin-proteasome pathway; however, in 
the presence of these ligands, ERα-AA was less efficiently degraded.  Furthermore, ERα-
AA was resistant to ICI-induced polyubiquitination, suggesting that these lysines are 
polyubiquitinated in response to the antiestrogen and demonstrate a novel role for these 
two lysines in the mechanism of action of ICI-induced receptor downregulation.  The 
reduced stability of ERα-AA in the unliganded state and the increased stability of ERα-
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 AA in the liganded state were concordant with reporter gene assays demonstrating that 
ERα-AA has lower basal activity but higher E2-inducibility than wtERα.  These data 
provide the first evidence that K302/303 protect ERα from basal degradation and are 
necessary for efficient E2 and ICI-induced turnover in breast cancer cells. 
 
INTRODUCTION 
The female sex-steroid hormone 17β-estradiol (E2) is essential for the normal 
growth and development of the reproductive system and the breast, and its action is 
mediated primarily by the estrogen receptor alpha (ERα) (358).  Aberrant E2 signaling 
through ERα has been strongly associated with disease development and the progression 
of breast cancer (206, 207).  Thus, appropriate ERα levels and subsequent E2-responses 
are precisely controlled, in part, by receptor turnover (183, 203-205). 
Cellular levels of ERα are maintained by distinct receptor degradation pathways 
that ultimately converge on the ubiquitin-26S proteasome system (182, 205, 290-295).  
Although both basal and ligand-induced ERα degradation are mediated by these 
proteolysis pathways (155, 230, 293, 294, 322), regulation of receptor degradation at the 
molecular level is highly dependent upon the physiological state and nature of the cellular 
stimulus.  For example, in the unliganded state (i.e., basal receptor turnover), ERα is 
targeted for degradation by dynamic interactions with heat shock proteins, cochaperones, 
and the ubiquitin ligase CHIP (Carboxyl terminus of Hsc70-interacting protein) (275, 
276).  In the presence of E2, hormone-bound receptors are targeted for degradation 
through a transcription-coupled pathway requiring new protein synthesis (thus blocked by 
the protein synthesis inhibitor cycloheximide) (292).  However, neither transcriptional 
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 activity nor new protein synthesis are needed for degradation of ERα when bound by a 
class of drugs called selective estrogen receptor downregulators or SERDs (ICI 182,780 
or fulvestrant; Faslodex®) (152, 155, 293).  Furthermore, drugs that inhibit Hsp90 
function (e.g., geldanamycin; GA) induce ERα downregulation by altering receptor-
Hsp90 interactions (275, 359, 360), in an ubiquitin ligase (CHIP)-dependent manner 
(275, 276).  In contrast, by dissociating receptor-chaperone complexes, selective estrogen 
receptor modulators (SERMs; e.g.,  tamoxifen; OHT) stabilize and protect ERα from both 
basal turnover and GA-induced degradation pathways (275, 294, 324).   
ERα protein turnover results from the formation of polyubiquitin chains on 
receptor lysines and its subsequent proteasomal degradation through the distinct 
degradation pathways described above.  However, of the 29 lysines found within ERα, 
none have been identified as residues targeted for polyubiquitination, and thus mediating 
receptor turnover.  Two possible candidates for receptor polyubiquitination are lysines 
K302 and K303, found within the hinge-region of ERα.  Lysines 302 and 303 have 
multiple regulatory functions, including receptor coactivator binding (33, 245, 361, 362), 
and in the presence of E2, K302 is monoubiquitinated by BRCA1/BARD1, a ubiquitin 
ligase (34)  The impact of K302 monoubiquitination on ERα stability is unknown, though 
these data reveal the availability of these hinge-region lysines for posttranslational 
modification, and we hypothesize that they may be suitable targets for polyubiquitination. 
ERα matures into a form capable of ligand binding and transactivation via 
progression through dynamic receptor-cochaperone interactions (363).  Several molecular 
chaperones, including Hsp70 and Hsp90, mediate ERα progression through this 
“foldosome” (297) by facilitating ERα interaction with cochaperones, including CHIP, 
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 Bag1 and p23 (Ptges3) (275, 276, 301, 364).  ERα hinge-region lysines 302 and 303 
reside between the DNA-binding and ligand-binding domains and are within the receptor 
surface area that interacts with Hsp90 (364, 365).  Therefore, mutation of these residues 
may alter ERα-Hsp90-cochaperone interactions, resulting in altered receptor progression 
through the foldosome.  We and others have shown that the cochaperone CHIP is an E3-
ubiquitin ligase required for basal ERα ubiquitination and proteasomal degradation (275, 
276).  We have also reported that geldanamycin (GA) increases ERα-Hsp90 association 
with CHIP, enhancing receptor degradation in the absence of ligand (275).  The 
cochaperones Bag1 and p23 have also been found in Hsp90-ERα complexes (276); 
however, their precise role in receptor turnover remains unknown.  Bag1 is found in early 
receptor-chaperone complexes and has been shown to link Hsp70 client proteins to the 
proteasome through its N-terminal ubiquitin-like domain (303, 304), suggesting that 
Bag1 may promote receptor degradation.  Conversely, p23 is found in mature receptor-
Hsp complexes and has been found to enhance basal and ligand-induced receptor 
transactivation (366).  In addition, p23 competes with CHIP for receptor association 
(302), suggesting that p23 may exert a stabilizing effect on ERα.  These previously 
defined actions suggest that Bag1, and/or p23, may play a functional role in mediating 
receptor turnover.  
In the present study, we utilized the ERα-negative breast cancer cell line C4-12 to 
stably express either wild-type (wt) ERα or ERα with lysine-to-alanine substitutions at 
K302 and K303 (“ERα-AA”) to investigate the role of these lysines in ERα 
polyubiquitination, turnover, and receptor-cochaperone interactions.  We demonstrate 
that lysines K302 and K303, by impeding receptor-CHIP and Bag1 interactions, and 
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 promoting p23 interactions, protect unliganded ERα from basal turnover. Additionally, in 
the presence of ligand, these two lysine residues control proteasome-mediated turnover 
and promote ICI-induced receptor polyubiquitination/degradation, thus revealing a novel 
role for these lysines in regulating receptor turnover.    
 
RESULTS 
Expression of wtERα and ERα-AA in C4-12 cells   
Site-directed mutagenesis was performed on wtERα in pcDNA.  Lysines at positions 302 
and 303 were mutated to alanines to create ERα-K302A,K303A (ERα-AA; Fig. 1A).  
Stable cell lines harboring wtERα or ERα-AA were established using C4-12 cells, an 
ERα-negative subline of MCF7 breast cancer cells (367).  Two wtERα and three ERα-
AA clones were chosen that had similar ERα expression levels.  ERα expression level 
among the clones was two-fold higher than MCF7 cells (Fig. 1B).  ERα mRNA levels in 
wtERα and ERα-AA clones were two and four-fold higher than MCF7 cells, respectively 
(Fig. 1C). The discrepancy between ERα-AA mRNA expression and protein levels was 
due to elevated basal ERα-AA degradation (described later).  
 
 
Lysines 302/303 reduce basal turnover of unliganded ERα 
 
As apo-(unliganded) ERα is a short-lived protein and undergoes constant degradation 
(290, 291, 296), we investigated the effect of hinge-region lysine mutations on stability of 
the unliganded receptor.   
 C4-12 cells stably expressing wtERα or ERα-AA were treated with the protein synthesis 
inhibitor cycloheximide (CHX) and apo-receptor degradation was then monitored by 
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Figure 1.  Expression of wtERα and ERα-AA in C4-12 cells.  A) Schematic showing the 
mutation of hinge-region lysines to generate ERα-AA.  Lysines 302 and 303 reside in the 
hinge-region between the DNA-binding domain (letter D) and the ligand-binding domain 
(letter E).  B) Representative ERα protein levels from two wtERα clones and three ERα-AA 
clones.  GAPDH was used as SDS-PAGE loading control.  ERα negative breast cancer C4-12 
cells were transfected with 1µg of pcDNA-ERα (wtERα) or ERα-K302A,K303A (ERα-AA) 
using Lipofectamine/PLUS and then treated with 800µg/ml G418 daily until single colonies 
were visible.  Multiple clones from each transfection were selected and expanded.  C) RT-
qPCR analysis of ERα mRNA levels.  EF1α mRNA level was used as internal control. 
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 immunoblot.  Levels of wtERα decreased in a time-dependent manner, displaying a half-
life of 3.85 ± 0.3 h (Fig. 2A, upper panel and Fig. 2C), in agreement with previous 
reports using CHX and other methods (43, 295, 296, 368, 369).  In comparison, increased 
(p<0.01) basal turnover of the mutant receptor ERα-AA was observed, and the half-life of 
ERα-AA was 1.04 ± 0.3 h (Fig. 2A, lower panel and 2C).  These results demonstrate that 
lysines 302/303 regulate ERα stability in the unliganded state by limiting basal receptor 
turnover.   
In the absence of ligand, apo-ERα is degraded by associating with heat shock 
proteins, including Hsp90, and the E3-ubiquitin ligase CHIP (275, 276).  The Hsp90 
inhibitor geldanamycin (GA), by blocking ATP binding to Hsp90 (311, 370-372), 
enhances ERα association with CHIP and increases receptor turnover (275, 359, 360).  
As lysines 302 and 303 reside in the Hsp90-interacting domain of ERα (364, 365), we 
investigated the effect of hinge region lysine mutation on GA-induced ERα turnover.  
Treatment of C4-12 cells stably expressing wtERα with GA displayed an increased 
(p<0.01) receptor turnover rate; the half-life of wtERα decreased from 3.85 ± 0.3 h to 
1.40 ± 0.3 h (Fig. 2B, upper panel and Fig. 2C).  GA treatment did not further increase 
ERα-AA basal turnover rate; receptor half-life was unchanged in the absence or presence 
of GA (1.04 ± 0.3 h vs. 0.92 ± 0.3 h, respectively; Fig. 2B, bottom panel and Fig. 2C).  
To summarize these findings, CHX and CHX/GA data are plotted together in Figure 2C.  
As shown, GA-induced wtERα turnover occurred at the same rate as ERα-AA basal and 
GA-induced turnover, suggesting that loss of lysines 302/303 and Hsp90 inhibition by 
GA share a common molecular mechanism to promote ERα degradation.  
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Figure 2.  Lysines 302/303 reduce basal turnover of unliganded ERα.  C4-12 cells stably 
expressing wtERα or ERα-AA were treated with A) CHX (25μg/ml) for 30 min before cell 
harvest at the indicated time points. B) CHX (25μg/ml) for 30 min, followed by GA (1μM) 
for the indicated times.  Experiments were performed in duplicate and repeated twice using 
two wtERα-expressing clones and three ERα-AA-expressing clones.  GAPDH was used as 
SDS-PAGE loading control.  C) Turnover rates of ERα and ERα-AA in the absence or 
presence of GA. The band density of the exposed film was evaluated with ImageJ software.  
Relative ERα levels (vs. untreated cells) are shown as means ± SE. **p<0.01. 
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Lysines 302/303 protect unliganded ERα from polyubiquitination 
 
Rapid ERα-AA protein turnover was observed in the absence of ligand (Fig. 2) and ERα-
AA mRNA levels were increased in ERα-AA clones that had equal levels of protein as 
wtERα (Fig. 1C), suggesting that loss of lysines 302/303 resulted in a destabilized 
receptor in the absence of ligand.  As ERα turnover is mediated by the ubiquitin-
proteasome pathway (182, 290-292), we investigated the role of K302 and K303 in 
ubiquitination of ERα.  Polyubiquitination assays in ERα-negative HeLa cells were 
performed as we have described previously (275).  Briefly, cells were transfected with 
equal amounts of wtERα or ERα-AA in addition to a hemagglutanin-tagged ubiquitin 
(HA-ubiquitin) or vector control plasmid.  Transfected cells were then treated with the 
proteasome inhibitor MG132 and allowed to accumulate polyubiquitinated proteins.  
Following MG132 treatment, immunoprecipitation was carried out using an ERα-specific 
antibody.  Proteins were then resolved by SDS-PAGE and the presence of ubiquitinated 
receptor was detected by immunoblotting with an HA antibody (polyubiquitinated 
species were detected as a high-molecular-weight ladder on the membrane).  In the 
absence of MG132, wtERα polyubiquitination levels remained low (Fig.3, lane 1), but 
subsequently increased after MG132 treatment (lane 3).  In contrast, in the absence of 
MG132, total immunoprecipitated (lower panel) and polyubiquitinated forms of ERα-AA 
species were notably more abundant than untreated wtERα (lane 5).  In addition, MG132 
treatment resulted in greater accumulation of polyubiquitinated forms of ERα-AA and 
total ERα-AA protein compared to wtERα (Fig. 3, lane 6). While it appeared that the 
mutant receptors may be more polyubiquitinated than wtERα, using these methods it was 
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Figure 3.  Lysines 302/303 protect unliganded ERα from polyubiquitination.  HeLa cells 
were transfected with equal amounts (250ng) of wtERα or ERα-AA along with 1µg HA-
ubiquitin, using LipofectAMINE/PLUS.  24 h later, the cells were treated with DMSO or 
MG132 for 5h, and then ERα immunoprecipitated with anti-ERα antibody.  Precipitated 
proteins were then resolved by SDS-PAGE and Western blot performed using an HA 
antibody.  Levels of immunoprecipitated ERα were also determined by probing with anti-ERα 
antibody (bottom panel).  
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 not possible to quantify the degree of polyubiquitination per receptor.  The mutant 
receptor displayed enhanced basal turnover rate and possibly enhanced basal 
polyubiquitination, indicating that lysine residues 302 and 303 may protect ERα from 
basal degradation by limiting apo-receptor ubiquitination .   
 
K302 and K303 reduce ERα association CHIP and Bag1 complexes 
We and others have previously shown that GA increases the association of ERα-
Hsp90 complexes with the E3-ubiquitin ligase CHIP, increasing receptor degradation 
(275 , 276).  As apo-ERα-AA had a rapid basal turnover rate that was not further 
increased by GA (Fig. 2B), we investigated the possibility that lysine mutations mimic 
the effects of GA by enhancing ERα-AA association with CHIP.  In addition, we wished 
to examine ERα interactions with the Bag1 cochaperone.  Bag1 links Hsp70 to the 
proteasome (303) and has also been detected in ERα complexes (276), but its precise role 
in ERα turnover has not been previously explored.  Finally, as GA inhibits p23 
interaction with Hsp90 (373) and also blocks p23-mediated enhancement of receptor 
transactivation (373, 374), we examined receptor-p23 interactions to determine whether 
p23 plays a stabilizing role on ERα.  To investigate the role of K302/303 in Hsp90, 
CHIP, Bag1 and p23 interactions with the receptor protein, and to determine if alterations 
in receptor-cochaperone interactions contributed to basal turnover of ERα-AA, we 
performed coimmunoprecipitation assays and analyzed Hsp90-cochaperone-receptor 
complexes in the presence or absence of GA.  Complexes were immunoprecipitated with 
an ERα-specific antibody and complexed proteins then identified by immunoblot, as 
shown in Figure 4A.  Relative receptor-cochaperone levels for CHIP, Bag1, and p23 are 
74
 shown in Figure 4B.  In untreated C4-12 cells stably expressing either wtERα or ERα-
AA, comparable levels of ERα, Hsp90, CHIP, Bag1, and p23 proteins were observed 
(Fig. 4A, lanes 1 & 6). Prior to treatment, wtERα coimmunoprecipitated with Hsp90, 
CHIP, the cytosolic form of Bag1 (36kDa), and p23 (Fig. 4A, upper panel, lane 2).  ERα-
AA also coimmunoprecipitated with these cochaperones, but association of ERα-AA with 
Bag1 and CHIP appeared to be enhanced, and only a weak association of ERα-AA with 
p23 was observed (Fig. 4A, lower panel, lane 7).  Overall levels of immunoprecipitated 
Hsp90 did not change throughout the duration of the experiment for both wtERα and 
ERα-AA (Fig. 4A), suggesting that changes in receptor turnover were not simply due to 
changes in ERα-Hsp90 interaction.  GA treatment resulted in an increase in association of 
CHIP and Bag1 with wtERα, with a concomitant decrease in p23 association (Fig. 4A, 
lane 3; Fig. 4B).  While GA treatment further enhanced the interaction of ERα-AA with 
CHIP and Bag1, the p23 association was completely abolished (Fig. 4A, lanes 8 & 9; 
4B).  These data suggest that K302/303 stabilize ERα by facilitating receptor progression 
through the foldosome, decreasing interaction with CHIP and Bag1, and increasing 
interaction with p23. 
 
Depletion of CHIP and Bag1 reduces ERα turnover, while p23 knockdown increases  
 
receptor turnover  
 
Previously, we have demonstrated that knockdown of CHIP via siRNA abolished 
basal and GA-induced ERα downregulation in both HeLa and MCF7 cells (275).  To 
further establish a role for CHIP, Bag1, and p23 in regulating ERα turnover, we used 
siRNA to investigate turnover of wtERα and ERα-AA in the absence of these 
cochaperones.  CHIP associated more strongly with rapidly-degraded ERα-AA (Fig. 4), 
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Figure 4.  K302 and K303 reduce ERα association with CHIP and Bag1 complexes. 
A) C4-12 ERα stable cells were pretreated with CHX (25μg/ml), followed by GA (1μM) for 
0-6h.   Proteins were harvested and receptor-cochaperone complexes immunoprecipitated 
with anti-ER or control IgG antibodies.  Proteins were resolved by SDS-PAGE and Western 
blot performed using specific antibodies against ER, p23, Bag1, and CHIP. B) Relative 
cochaperone/ER levels for CHIP, Bag1, and p23.  Cochaperone/ER ratios were normalized to 
cochaperone/wtERα levels for untreated cells.   
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 and ERα-AA was also resistant to GA-induced degradation (Fig. 2), suggesting that ERα-
AA degradation is CHIP-dependent.  siRNA against CHIP was performed in HeLa cells 
as we have described previously (275).  HeLa cells were transfected with equal amounts 
of wtERα or ERα-AA plasmid, with or without the CHIPi vector, and cells were then 
treated with CHX followed by vehicle or GA).  Empty vector and mock transfection had 
no effect on CHIP levels (Fig. 5A, top panel).  In addition, basal and GA-induced 
downregulation in the vector control cells were not different than that of cells treated in 
Figure 2 and were used as controls for CHIPi assays.  Expression of CHIPi decreased the 
level of CHIP by over 60% (Fig. 5A, top panel), and this was sufficient to completely 
block basal turnover of both wtERα and ERα-AA (Fig. 5A, middle panel).  CHIPi also 
blocked GA-induced turnover of wtERα and ERα-AA (Fig. 5A, bottom panel), thus 
confirming that CHIP mediates basal and GA-induced turnover of wtERα and ERα-AA.   
Similar to CHIP, association of Bag1 was stronger with ERα-AA than wtERα.  As 
this protein has been shown to link Hsp70 to the proteasome (303, 304), C4-12 cells were 
transfected with siRNA against Bag1 or scrambled (Sc) siRNA to investigate whether 
Bag1 is involved in ERα turnover.  Scrambled siRNA or mock transfection had no effect 
on Bag1 levels (Fig. 5B, top panel), and basal and GA-induced ERα downregulation was 
not different from untransfected cells (see Fig. 2C).  Scrambled siRNA was therefore 
used as a control for Bag1 siRNA treatment.  Knockdown of Bag1 in C4-12 stable clones 
delayed basal turnover of wtERα, increasing (p< 0.01) its half-life from 3.14 ± 0.3h to >6 
h (Fig. 5B, middle panel).  Bag1 knockdown also delayed ERα-AA basal degradation, 
increasing (p< 0.01) the mutant receptor half-life from 1.2 ± 0.3 h (see Fig. 4A) to 3.4 ± 
0.2 h (Fig. 5B, middle panel).  GA-induced downregulation of both wtERα and ERα-AA 
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Figure 5A.  Depletion of CHIP and Bag1 reduces ERα turnover, while p23 knockdown 
increases receptor turnover.  For siRNA CHIP experiments, HeLa cells were transfected 
with equal amounts of wtERα or ERα-AA along with CHIPi, pcDNA empty vector, or 
transfection reagent only (Mock).  24 h later, cells were pretreated with CHX followed by 
vehicle or GA (1μM) for the time periods indicated.  Western blots were then performed 
against CHIP and ERα, using specific antibodies.   
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Figure 5B) siRNA against Bag1 (Bag1i, 50nM) and control scrambled oligo (Sc, 100nM) were 
transfected into C4-12 stable cells using the siRNA transfection reagent Dharmafect1 for 3 d.  72 
h after transfection, cells were pretreated with CHX, followed by vehicle or GA for the indicated 
time periods.  Protein levels were examined by Western blot using specific antibodies. The band 
density of exposed film was evaluated with ImageJ software.  Sc (scrambled siRNA) and mock 
(M; Dharmafect1 only) were specificity and transfection controls.  GAPDH was used as SDS-
PAGE loading control.  Experiments were performed in duplicate and repeated twice using two 
wtERα and three ERα-AA clones.  **p<0.01.    
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Figure 5C) siRNA against p23 (p23i, 100nM), and control scrambled oligo (Sc, 100nM) were 
transfected into C4-12 stable cells using the siRNA transfection reagent Dharmafect1 for 3 d.  72 
h after transfection, cells were pretreated with CHX, followed by vehicle or GA for the indicated 
time periods.  Protein levels were examined by Western blot using specific antibodies. The band 
density of exposed film was evaluated with ImageJ software.  Sc (scrambled siRNA) and mock 
(M; Dharmafect1 only) were specificity and transfection controls.  GAPDH was used as SDS-
PAGE loading control.  Experiments were performed in duplicate and repeated twice using two 
wtERα and three ERα-AA clones.  **p<0.01.    
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 was delayed by Bag1 knockdown;  wtERα half-life was increased (p< 0.01) from 1.40 ± 
0.3 h  to >6 h, and ERα-AA half-life increased (p< 0.01)  from 0.92 ± 0.3 h to 3.3 ± 0.2 h 
(Fig. 5B, lower panel;  and see Fig. 2C), thus confirming that Bag1 promotes both basal 
and GA-induced receptor turnover.   
 
The cochaperone p23 is associated with mature Hsp90 complexes and enhances 
ERα transactivation (365, 366).  ERα-AA bound less strongly to p23 than wtERα; 
consequently, we transfected C4-12 cells with siRNA against p23 or scrambled siRNA to 
assess whether loss of p23 would destabilize ERα and enhance its turnover.  Scrambled 
siRNA or mock transfection had no effect on p23 levels (Fig. 5C, top panel), and basal 
and GA-induced ERα downregulation in cells transfected with scrambled siRNA or mock 
transfection were not different from untransfected cells (see Fig. 2C).  Scrambled siRNA 
was therefore used as a control for p23 siRNA treatment. Knockdown of p23 enhanced 
wtERα turnover in CHX-treated cells; receptor half-life decreased from 3.1 ± 0.3 h to 
0.85 ± 0.1 h (Fig. 5C, middle panel).  Moreover, GA-induced turnover of wtERα was 
also increased after p23 knockdown (p< 0.01), with its half-life decreased from 1.5 ± 0.2 
h to 0.75 ± 0.2 h (Fig. 5C, lower panel).  However, p23 knockdown had no effect on 
basal or GA-induced turnover of ERα-AA, as the half-life of ERα-AA was similar in the 
presence or absence of p23 siRNA (1.04 ± 0.3 h vs. 0.94 ± 0.1 h; Fig. 5C, middle panel).  
This was not unexpected, as low levels of p23 were detected in ERα-AA-
immunoprecipitated complexes (Fig. 4A).  These results demonstrate that p23 exerts a 
stabilizing effect on ERα.  Together, these data suggest that CHIP and Bag1 promote, 
while p23 inhibits, basal and GA-induced ERα degradation.  Furthermore, K302/303 
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 appear to be important for the association of ERα with these cochaperones during basal 
and GA-induced receptor turnover, by decreasing receptor association with the 
degradation-promoting cochaperones CHIP and Bag1, while increasing association with 
the stabilizing cochaperone p23. 
 
Hinge-region lysines promote ligand-induced receptor turnover 
Ligand binding dissociates ERα from Hsp90 complex and directs ERα toward 
alternative degradation pathways (293, 294, 322).  To investigate the effect of hinge-
region lysine mutations on ligand-mediated receptor turnover, C4-12 cells were treated 
with various ligands, and changes in ERα stability were monitored by immunoblot.  As 
shown, E2 induced ERα downregulation following transcriptional activation, decreasing 
wtERα protein level in a time-dependent manner (Fig. 6A, upper panel), while impairing 
degradation of ERα-AA under the same experimental conditions (Fig. 6A, lower panel).  
ICI, which directly targets ERα for degradation (152, 155, 192, 293), similarly reduced 
wtERα levels to less than 50% by 1 h (Fig. 6B, upper panel); this same level of reduction 
in ERα-AA levels was not seen until 3 h after ICI treatment (Fig. 6B, lower panel).  CHX 
pretreatment did not significantly affect ICI-induced downregulation of either receptor 
(Fig. 6C), confirming that the slower decline of ERα-AA protein in the presence of ICI 
was due to impaired receptor degradation rather than elevated synthesis of the mutant ER.    
These data suggest two possible roles for ligand action on ERα-AA:  1) Ligand binding 
may rescue ERα-AA from interaction with CHIP and Bag1, protecting it from the rapid 
basal turnover observed in Figure 2B; or 2) ERα-AA may be less sensitive to ligand-
induced degradation.   
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Figure 6. Hinge-region lysines promote ligand-induced receptor turnover.  C4-12 ERα 
stable cells treated with A) E2 (10nM), or B) ICI (100nM) for the indicated times.  
Experiments were performed in duplicate and repeated twice using two ERα and three ERα-
AA clones.  GAPDH was used as SDS-PAGE loading control.  The band density of exposed 
film was evaluated with ImageJ software.  Relative ERα levels (vs. untreated cells) are shown 
in the corresponding graph as the mean ± SE. ** p<0.01.   
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Figure 6. Hinge-region lysines promote ligand-induced receptor turnover.  C4-12 ERα 
stable cells treated with C) CHX (25ug/ml  30’ followed by 100nM ICI) or D) OHT (100nM) 
for the indicated times.  Experiments were performed in duplicate and repeated twice using 
two ERα and three ERα-AA clones.  GAPDH was used as SDS-PAGE loading control.  The 
band density of exposed film was evaluated with ImageJ software.  Relative ERα levels (vs. 
untreated cells) are shown in the corresponding graph as the mean ± SE. ** p<0.01.   
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 By dissociating receptor-chaperone complexes, 4-hydroxytamoxifen (OHT) 
stabilizes ERα and protects receptors from basal turnover (275, 294, 324). As expected, 
wtERα was stabilized by OHT (Fig. 6D, upper panel), and OHT caused ERα-AA levels 
to accumulate (Fig. 6D, lower panel), suggesting that OHT was able to antagonize rapid 
ERα-AA basal turnover, further implicating lysines 302/303 in protecting ERα from basal 
turnover.   
 
Hinge-region lysines promote ligand-induced receptor polyubiquitination  
 
It is well known that both E2 and ICI stimulate receptor ubiquitination (192, 222, 
291, 375) and its subsequent degradation by the 26S proteasome (291).  Consequently, 
our observation that these ligands were unable to efficiently degrade ERα-AA indicated 
that ERα-AA may be resistant to polyubiquitination.  To investigate this possibility, we 
measured the ubiquitination of ERα and ERα-AA after inhibiting the proteasome with 
MG132 and stimulating receptor ubiquitination with E2 or ICI.  ERα-negative HeLa cells 
were transiently transfected with equal amounts of wtERα or ERα-AA expression 
constructs, along with the HA-ubiquitin construct.  Cells were then pretreated with 
DMSO or MG132 before treatment with DMSO, E2, or ICI.  Subsequently, ERα was 
immunoprecipitated with an ERα-specific antibody and HA-polyubiquitinated species of 
ERα were detected as a high-molecular-weight ladder on the membrane.  As shown, 
MG132 treatment of cells containing wtERα resulted in accumulation of 
polyubiquitinated receptor forms (Fig. 7A, lane 1 vs. 2).  After E2 or ICI treatment, 
similar levels of ubiquitinated wtERα were observed, presumably due to proteasomal 
degradation of ubiquitinated receptors (Fig. 7A, lane 3 & 5).  As expected, proteasome 
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 inhibition with MG132, prior to E2 or ICI treatment, resulted in the accumulation of 
polyubiquitinated wtERα (Fig. 7A, lanes 4 & 6).   
In ERα-AA transfected cells, MG132 treatment also resulted in accumulation of 
polyubiquitinated receptor forms, but to a greater extent than cells transfected with 
wtERα (Fig. 7, compare lanes 1-2 vs. 7-8).  In the absence of MG132, E2 treatment did 
not further increase ERα-AA ubiquitination (Fig. 7B, lanes 9); however, MG132 
pretreatment increased polyubiquitinated ERα-AA in the presence of E2 (Fig. 7B, lanes 
10).  Ubiquitination levels of ERα-AA and wtERα in the presence of E2 were similar 
(Fig. 7, lane 3 vs. 9).  ICI induced modest polyubiquitination of ERα-AA in the absence 
of MG132 (Fig. 7B, lane 11), although these levels were not different than ICI-induced 
polyubiquitination in the presence of MG132 (Fig. 7B, lane 11 vs. 12).  Importantly, ICI-
treated ERα-AA protein levels were slightly higher than ICI-treated wtERα levels, but 
less polyubiquitination occurred in ERα-AA cells (Fig 7. lane 12).  An ERα mutant with 
lysine-to-arginine substitutions, ERα-K302R/K303R (ERα-RR), shared a similar 
ubiquitination profile to that of ERα-AA. In contrast to wtERα, both mutant receptors 
were heavily ubiquitinated in the absence of ligand and no further ubiquitination was 
observed in response to ICI treatment (Fig. 7C). These results indicate that K302/303 
may be direct targets for polyubiquitination in the presence of ICI.  We therefore report a 
previously undescribed role for these hinge-region lysines in mediating receptor 
polyubiquitination induced by the pure antiestrogen. 
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Figure 7.  Hinge-region lysines 
promote ligand-induced receptor 
polyubiquitination.  HeLa cells were 
transfected with equal amounts (250ng) 
of A) wtERα B) ERα-AA or C) 
ERαK302R/K303R, along with 1μg 
HA-ubiquitin using 
LipofectAMINE/PLUS. Transfected 
cells were pretreated with vehicle 
(DMSO) or MG132 (25µM) for 1 h, 
followed by DMSO, E2 (10nM) or ICI 
(100nM) for 4 h.  ERα was then 
immunoprecipitated with anti-ERα 
antibody.  Precipitated proteins were 
resolved by SDS-PAGE and Western 
blot performed with an HA antibody.  
Levels of immunoprecipitated ERα 
were also determined by probing with 
an anti-ERα antibody (lower panel).  
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K302 and K303 contribute to ERα target gene transactivation   
 
While E2 binding increases ERα transactivation, apo-ERα is also capable of 
eliciting basal transcriptional activity (151).  Mutating K302 and K303 resulted in rapid 
ERα turnover in the absence of ligand (Fig. 2), but increased receptor stability in the 
presence of E2 (Fig. 6).  It was therefore of interest to examine whether these two hinge 
region lysines play a functional role in ERα transactivation in the presence and absence 
of E2.  To examine transcriptional competency of ERα-AA, basal and E2-induced 
receptor activity was examined utilizing an E2-responsive chloramphenicol 
acetyltransferase construct (ERE-CAT (183)).  C4-12 stable cell lines were transiently 
transfected with an ERE-CAT reporter and treated with E2.  The absolute CAT levels in 
untreated (DMSO) ERα-AA-expressing cells exhibited lower (p<0.01) transcriptional 
output than cells expressing wtERα (0.15±0.02 vs. 1.62±0.09 pg/mg lysate; Fig. 8A).  E2 
treatment elicited a response in both cell lines, but CAT-expression remained lower 
(p<0.01) in ERα-AA-expressing cells vs. wtERα-expressing cells (0.98 ±0.06 vs. 
2.67±0.06 pg/mg lysate), suggesting an overall reduction in ERα-AA mediated 
transcriptional activity.  Normalized CAT values (untreated CAT levels set to one; Fig. 
8B) revealed that E2-induced fold changes in CAT levels were higher (p<0.01) for ERα-
AA compared to wtERα (11.12±2.58 fold vs. 2.11±0.19 fold), suggesting that mutation of 
K302/303 results in overall lower transcriptional activity, with enhanced E2-inducibility.      
In a more physiologically relevant context, we investigated the expression of the 
endogenous E2-responsive gene cathepsin D in C4-12 cells.  Induction of cathepsin D 
levels by E2 was observed in both wtERα and ERα-AA C4-12 cells (Fig. 8C). Similar to 
CAT assays, at all time points examined, absolute levels of cathepsin D mRNA were 
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Figure 8.  A) K302 and K303 contribute to ERα target gene transactivation.  A) Estrogen-
responsive CAT assays were performed in C4-12 ERα stable cells.  Cells were transfected with 
250 ng ERE-Vit-CAT and then treated with DMSO or E2 (10nM) for 48 h.  Cells were then 
lysed and total protein (100μg) from each treatment group used to determine CAT levels.  B) 
Relative levels of CAT expressed as fold-change of E2-induced gene expression by setting 
untreated levels to 1.  The E2-induced transactivation for ERα-AA was significantly higher than 
for wtERα.  Results were expressed as mean ± SE from three independent experiments.  ** 
p<0.01.  C) Transactivation of cathepsin D expression by ERα-AA and wtERα.  Induction of the 
E2- responsive gene cathepsin D was determined by RT-qPCR analysis after E2 treatment (10 
nM) of C4-12 cells for the indicated time periods.  Cathepsin D levels were normalized with 
EF1α.  D)  Relative levels of cathepsin D mRNA were expressed as fold-change of E2-induced 
gene expression by setting untreated levels to 1.  Results are the mean ± SE from three 
independent experiments. **p<0.01.   
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 lower (p<0.01) in cells expressing ERα-AA (Fig. 8C).  However, when normalized 
(untreated mRNA level set to 1), the fold-change of E2-induced cathepsin D mRNA 
expression was greater (p<0.01) in cells expressing ERα-AA (Fig. 8D).  The basal and 
E2-induced expression levels of cathepsin D mRNA in wtERα C4-12 cells were 
comparable to that in ERα-positive MCF7 cells (Fig. 8 E-G), while cathepsin D mRNA 
level in the parental ERα-negative C4-12 cells was not affected by E2 treatment (data not 
shown).    
The ERα hinge-region contains the receptor nuclear localization sequences (376). 
To determine whether the low transcription activity of ERα-AA is caused by altered 
cellular localization, we examined nuclear translocation of wtERα and ERα-AA. In the 
absence of ligand, ERα-AA was found equally distributed between cytosolic and nuclear 
fractions, while the majority of wtERα protein was found in the nuclear fraction (Fig 8I). 
This result is in agreement with coimmunoprecipitation data which revealed elevated 
association of ERα-AA with cytosolic cochaperones (Fig 4).  Both receptors efficiently 
translocated to the nucleus in response to E2 treatment, suggesting that the decreased 
ERα-AA transcription activity in response to E2 is not due to impaired nuclear 
localization. 
E2-induced cathepsin D expression was also examined after siRNA knockdown 
of cochaperones to determine the relative contribution of each cochaperones to receptor 
transcriptional activity.  CHIP knockdown increased basal and E2-induced cathepsin D 
mRNA levels in both wtERα and ERα-AA expressing cells (Fig. 8E-G).  Notably, CHIP 
knockdown had a greater effect on ERα-AA-mediated gene expression. CHIPi increased 
basal and E2-induced wtERα activity by 2-fold, while increased basal and E2-induced 
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Figure 8E-G)  Cochaperone knockdown alters ERα-mediated transcriptional output. 
MCF7 cells (F), wtERα C4-12 cells (G) or ERα-AA C4-12 cells (H) were transfected with 
siRNA against CHIP, Bag1, and p23 for 2d.  E2-induction of cathepsin D was determined by 
RT-qPCR analysis after 4h E2 treatment (10 nM).  Cathepsin D levels were normalized with 
EF1α and expressed as mean ± SE of results from two MCF7 replicates, two wtERα clones, 
or three ERα-AA clones. Scrambled oligo (Sc) was included as control.  H)  Lysines 302/303 
do not modulate E2-sensitivity.  ERE-Luciferase assays were performed in C4-12 ERα 
stable cells.  Cells were transfected with 2x-ERE-ps2-luc and then treated with increasing 
dose of E2 (0-10nM) for 12 h.   Luciferase activity was measured and normalized to 
cotransfected CMV-β-gal, and compared to vehicle (DMSO) treated cells.  Values are 
expressed as mean ± SE of three independent experiments, each performed in triplicate. The 
EC50 values were calculated using 95% confidence function of Prism software. The EC50 
values are shown as dashed lines and solid lines for wtERα and ERα-AA, respectively.  I) 
Nuclear localization of wtERα and ERα-AA.  C4-12 cells were pretreated with vehicle 
(DMSO) or E2 (10nM) for 20 minutes.  Whole cell fractions (W) or nuclear extracts fractions 
(N) were isolated and Western blot was performed for ERα.  GAPDH was used as an SDS-
PAGE loading control.      
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Figure 8I) Nuclear localization of wtERα and ERα-AA.  C4-12 cells were pretreated with 
vehicle (DMSO) or E2 (10nM) for 20 minutes.  Whole cell fractions (W) or nuclear extracts 
fractions (N) were isolated and Western blot was performed for ERα.  GAPDH was used as 
an SDS-PAGE loading control.      
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 ERα-AA activity by 3-fold.  The enhanced interaction between ERα-AA and CHIP is 
clearly involved in decreasing the transcriptional capacity of the mutant receptor.  Bag1 
knockdown did not significantly alter cathepsin D expression mediated by either ERα-
AA or wt-ERα.  Knockdown of p23 significantly decreased both basal and E2-induced 
cathepsin D levels in wtERα-expressing cells, but not in ERα-AA cells, in agreement 
with a previous report that p23 enhances receptor activity (377).  It is not surprising that 
knockdown of p23 had no effect on ERα-AA-mediated cathepsin D expression, as ERα-
AA does not significantly interact with p23 (Fig. 4).   
In both CAT and cathepsin D assays, mutation of K302 and K303 resulted in 
lower transcriptional output in the presence and absence of ligand, suggesting that these 
residues are critical for full ERα transcriptional competence.  The effect of hinge region 
mutation on ERα sensitivity to E2 has recently been investigated, with disparate findings 
(245, 378).  The discordant reports on this issue appear be due to experiments using 
different cellular environments.  To shed light on this issue, we examined the sensitivity 
of ERα-AA to E2 in the previously unexplored C4-12 cellular background.  C4-12 ERα 
clones were transfected with the estrogen-responsive luciferase reporter 2x-ERE-pS2-luc 
(183), then treated with E2 (range 10-16 to 10-9 M).  A dose-responsive increase in 
luciferase activity was observed for both wtERα and ERα-AA transfected cells after E2 
treatment (Fig. 8H).  Sigmoidal curve-fit analysis was then used to determine the 
concentration of E2 inducing 50% maximum luciferase activity (E2 EC50).  There was no 
significant difference in sensitivity of wtERα and ERα-AA to E2: EC50 was 10-12.315 M vs. 
10-12.44 M for wtERα vs. ERα-AA, respectively (Fig. 8H; indicated by dashed and solid 
vertical lines on the X-axis).  Taken together, these results demonstrate a role for 
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 K302/303 in promoting both basal and E2-induced transactivation, without altering 
hormone sensitivity.   
 
DISCUSSION 
Protein turnover and degradation pathways, which ultimately converge on the 
ubiquitin-26S proteasome system (182, 205, 290-295), are the predominant mechanisms 
for regulating cellular levels of ERα (352, 375).   Distinct mechanisms that downregulate 
ERα and other steroid hormone nuclear receptors promote lysine polyubiquitination and 
subsequent proteasome-mediated receptor degradation (379).  However, none of the 29 
ERα lysine residues have been identified as direct polyubiquitination sites that stimulate 
ERα turnover.  While previous studies have suggested that ERα lysines K302 and K303, 
found within the hinge-region, can serve multiple regulatory functions (245, 362), the 
role of these two lysines in receptor turnover has not been established.  In the present 
study, we focused on how K302 and K303 control ERα ubiquitination and turnover.  By 
mutating these two lysines, we demonstrate that K302 and K303 promote ERα stability in 
the unliganded state, allow for efficient receptor turnover in response to E2, and finally 
promote polyubiquitination and turnover in response to the antiestrogen ICI.  The 
potential roles of lysines 302/303 in ERα degradation pathways have been summarized in 
a model in Figure 9.  
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Figure 9.  Lysines 302/303 protect ERα from basal turnover and promote E2 and SERD-
induced degradation.  ERα is degraded via three distinct downregulatory pathways that 
converge on the 26S proteasome.  (1) Basal Turnover (left pathway).  ERα protein folding 
and maturation begins in a multi-protein Hsp70/90 chaperone complex (shown as a simplified 
complex at top).  In the absence of ligand, ERα is ubiquitinated by CHIP, and ubiquitinated 
receptors are recognized by Bag1 and delivered to the proteasome.  Apo-ERα turnover (basal 
turnover) is enhanced by both GA and lysine 302/303 mutation, through increased complex 
association with CHIP and Bag1.  (2) Transcription-coupled ERα turnover (right pathway).   
ERα is dynamically maintained in a mature receptor complex that includes p23.  Upon 
binding of E2, ERα disassociates from the Hsp90 complex and is thus protected from CHIP-
mediated degradation.  Activation of E2-responsive target genes results in receptor 
ubiquitination and degradation in a transcription-coupled manner.  OHT stabilizes receptor-
DNA complexes and blocks both basal and transcription-coupled turnover.  ERα-AA blocks 
transcription and transcription-coupled turnover by limiting p23-mediated receptor 
maturation.  (3) SERD-mediated ERα degradation (middle pathway). The antiestrogen ICI 
stimulates ERα release from Hsp complexes and blocks receptor transactivation, sequestering 
ERα in the nuclear matrix, and triggering rapid receptor ubiquitination and degradation.  
Lysines 302/303 are required for ICI-induced polyubiquitination and turnover.  As ERα 
degradation is dependent on the 26S proteasome, the proteasome inhibitor MG132 blocks all 
receptor turnover pathways. 
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It is possible that lysine mutations resulted in a misfolded, unstable receptor.  In 
the present study, it is not possible to determine whether ERα-AA is misfolded, as the 
mutant receptor favors the CHIP/proteasome-dependent pathway, which degrades both 
mature and misfolded receptors (275, 276).  However, we do not believe that ERα-AA 
was misfolded, as crystal structures are not possible in this region due to the flexible 
nature of the hinge region (36), suggesting mutation does not disrupt secondary protein 
structures.  Additionally, Fuqua et al. reported that a similar mutant, ERα-K303R, bound 
E2 and OHT with the same affinity as wtERα (245).  
ERα lysines 302/303, located within the Hsp90/ER interface (364, 365), may 
influence receptor stability by altering receptor-Hsp90-cochaperone interactions.  Though 
both receptors associated similarly with Hsp90, coimmunoprecipitation analysis revealed 
an increased interaction of ERα-AA with CHIP and decreased interaction with p23, 
compared to wtERα.  We have previously shown that Hsp90 inhibitor geldanamycin 
(GA) induces receptor association with CHIP and dissociation from p23, resulting in 
receptor ubiquitination and degradation by the 26S proteasome (275).  These 
observations suggest that loss of lysine 302/303 and GA may promote receptor 
degradation through the same CHIP-mediated protein degradation pathway. In support of 
this notion, both ERα-AA turnover and GA induced wtERα could be blocked by OHT 
(Fig.  6), which interrupts ERα interaction with HSP90/cochaperones.   
The cochaperone Bag1 has been also found to associate with ERα (276), but to 
date, an association between Bag1 and ERα turnover has not been established.  Bag1 
functions as a nucleotide exchange factor (305) that may destabilize protein-Hsp 
complexes and promote delivery of ubiquitinated client proteins to the proteasome.  The 
96
 glucocorticoid receptor (GR), another Hsp70/90 client, is also ubiquitinated by CHIP 
(302), and following CHIP-mediated ubiquitination, Bag1 delivers GR to the proteasome 
(309).  Similar to the results of the present study with ERα and CHIP, mutations in the 
Hsp90-interacting residues of GR likewise resulted in altered GR-Hsp90-cochaperone 
dynamics and receptors that were immune to GA-induced turnover (374, 380, 381).  
Therefore, the mechanism by which ERα is delivered to the proteasome is likely similar 
to Bag1-mediated delivery of GR.  Our results further suggest that Bag1 promotes basal 
and GA-induced receptor degradation, as ERα-AA-Bag1 association increased following 
GA treatment, while Bag1 siRNA delayed receptor turnover (Figs. 4 and 5). As with GR, 
Bag1 may again cooperate with CHIP, delivering polyubiquitinated ERα to the 
proteasome through its proteasome-recognition domain (303, 309).  CHIP and Bag1 
cooperation may therefore represent a common basal turnover mechanism for nuclear 
receptor degradation.  
While CHIP and Bag1 are found in early receptor complexes, the ERα 
cochaperone p23 is found in late/mature receptor complexes (366).  p23 has been shown 
to enhance both basal and ligand-induced ERα transactivation (377) and also to compete 
with CHIP for Hsp90 binding (302).  We found that wtERα was rapidly degraded upon 
p23 knockdown (Fig. 5C), suggesting that p23 exerts a stabilizing effect on the receptor.  
In addition, ERα-AA preferentially associated with CHIP and Bag1 and also had less 
affinity for p23 (Fig. 4).    Knockdown of p23 expression decreased wtERα-mediated 
cathepsin D gene expression, but not ERα-AA. In contrast, CHIP knockdown had a 
greater effect on ERα-AA-mediated gene expression (Fig. 8E-G). These results suggest 
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 that p23 positively regulates ERα activity by stabilizing receptors, while CHIP limits 
ERα function by promoting receptor degradation.    
Taken together, these data indicate that lysines 302/303 may encourage receptor 
association with p23, facilitating progression of ERα through the foldosome and 
increasing receptor transactivation potential.  Numerous mutations that stabilize ERα in 
the presence of ligand also block E2-mediated receptor transactivation (4).  Indeed, ERα-
AA was stabilized in the presence of E2 and the mutant receptor was less 
transcriptionally competent than wtERα (Fig. 8).   Alterations in the hinge-region  may 
reduce basal ERα-AA-mediated transactivation due to disruption of an ERα prototypical 
nuclear localization sequence (pNLS) located between K299 and K303 (376).  We 
observed increased cytosolic retention of unstimulated ERα-AA, which may contribute to 
the low basal transcription activity observed in ERα-AA cells and the elevated ERα-AA 
interaction with cytosolic CHIP.   Elevated basal ERα-AA degradation may also explain 
the discrepancy between ERα-AA mRNA expression and protein levels.  In untreated 
cell, the level of ERα-AA mRNA in the clones was twice that of wtERα (Fig. 1).  As the 
half-life of apo-ERα-AA was significantly less than wtERα (Fig. 2), and ERα-AA 
displayed elevated polyubiquitination in the absence of ligand (Fig. 3), it is likely that 
ERα-AA clones maintained similar protein levels as wtERα clones due to rapid ERα-AA 
protein degradation.   
 Upon ligand binding, nuclear receptors dissociate from Hsp90-CHIP complexes 
and are directed toward alternative downregulatory pathways (294, 322, 324).  Treatment 
with E2 moves ERα toward a transcription-coupled degradation pathway (379).  
Concordantly, we observed increased polyubiquitination and turnover of wtERα after E2.  
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 In contrast to the wild type receptor, ERα-AA was stabilized by E2.  While ERα-AA was 
more stable than wtERα following E2 treatment, E2-induced polyubiquitination of ERα-
AA did not appear to be different from wtERα.  The stabilization of ERα-AA by E2, 
without decreased polyubiquitination, may be due to its protection from rapid basal 
turnover observed in the unliganded condition (Fig. 2).  Alternatively, K302/303 may be 
required for efficient E2-induced turnover, either by interacting with degradation 
machinery directly or by serving as sites of posttranslational modification that recruit 
degradation machinery.  In fact, K302/303 have been reported to be sites for acetylation 
(31) and sumoylation (32), in addition to K302 monoubiquitination (34), so it is possible 
that altered receptor stability was due to loss of a posttranslational modification site. 
However, a recent report has shown ERα to be acetylated at lysines 266/268 and 
specifically not at lysines 302/303 (30).  As lysines 266/268 are also sumoylation sites 
(32), E2-induced monoubiquitination of lysines 302/303 by BRCA1/BARD1 (34) 
remains the likely signal for initiating E2-induced polyubiquitination and receptor 
turnover.   
In contrast to E2 treatment, K302 and K303 appeared to play a significant role in 
ICI-induced receptor polyubiquitination (Fig. 7).  ERα-AA was more stable than wtERα 
upon ICI treatment and the mutant receptor had markedly diminished polyubiquitination.  
As further ERα-AA polyubiquitination did not occur in the presence of the antiestrogen, 
this raises the strong possibility that lysines 302/303 are ICI-induced polyubiquitination 
targets.  This is the first report to identify lysines whose mutation results in altered ICI-
induced receptor ubiquitination, providing insight into the mechanism of ICI action.  
Both ERα-AA and ERα-RR were resistant to ICI-induced polyubiquitination.  Lysine 
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 mutation to alanine removes positive charges, while lysine mutation to arginine preserves 
positive charges.  As both ERα-AA and ERα-RR have a similar ubiquitination profile, we 
suggest that the charge of the residues is not responsible for directing receptor 
ubiquitination.  Rather, it may be the loss of post-translational modifications of these 
lysines that is responsible for the decrease in ICI-induced polyubiquitination, raising the 
possibility that lysines 302/303 are preferential ubiquitination sites in response to ICI.  
Furthermore, it has been recently shown that K302 is monoubiquitinated in the presence 
of ligand (34); it is very likely that additional K302 polyubiquitin attachment could occur 
in the presence of ICI, thus facilitating receptor degradation.    
 In conclusion, we propose that lysines 302/303 regulate basal ERα turnover 
pathways by preventing interaction with the cochaperones CHIP and Bag1 in the absence 
of ligand.  We also report that K302/303 appear to function as polyubiquitination sites in 
the presence of ICI.  These results reveal that K302/303 play a multifaceted role in 
regulating receptor stability and also highlight a previously undescribed role for these 
hinge-region lysines in the mechanism of ICI action.  Using mass spectrometry, we are 
investigating which of the 29 ERα lysines are ubiquitinated during receptor degradation 
and attempting to identify the specific ubiquitin ligase(s) involved in these processes.  It 
is well established that deregulation of ERα stability occurs in breast cancer cells.  
Consequently, understanding the role of receptor lysines in ERα turnover will aid in 
understanding the mechanisms of antiestrogen therapies and may also facilitate the 
development of novel ERα downregulators.   
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 MATERIALS AND METHODS 
Materials   
The following antibodies and reagents were used in this study:  anti-ERα (HC-20; Santa 
Cruz Biotechnology, Inc.); anti-glyceraldehyde phosphate dehydrogenase (GAPDH) 
(Chemicon International); Anti-HA (Roche); anti-p23 (Abcam) anti-CHIP and anti-Bag1 
(Affinity Bioreagents), anti-Hsp90 (Stressgen). SuperSignal West Pico chemiluminescent 
substrate (Pierce); protease inhibitor cocktail set III (PIC III) and Protein-G agarose beads 
(Calbiochem-Novabiochem); LipofectAMINE/PLUS reagents, G418, and cell culture 
reagents (Invitrogen); TrueBlot anti-mouse IgG beads (eBioscience).  FuGENE6 and 
CAT-ELISA kit (Roche Applied Science); ICI 182,780 (Tocris Cookson Ltd.); CHX, E2, 
GA, MG132, and OHT (Sigma); passive lysis buffer and luciferase assay system 
(Promega); fetal bovine serum and dextran-coated charcoal-stripped FBS (Hyclone 
Laboratories, Inc.); cell culture supplementary reagents (Life Technologies, Inc.).  siRNA 
and DharmaFect1 transfection reagent (Dharmacon). 
 
Plasmid Constructs    
pcDNA-ERα and pcDNA-ERα-K302A,K303A constructs were kindly provided by Dr. 
H. Nakshatri (Indiana University School of Medicine).  ERα lysines 302 and 303 within 
the pcDNA plasmid were changed to alanines by site-directed mutagenesis using the 
QuikChangeTM site-directed mutagenesis kit (Stratagene) to generate ERα-
K302A,K303A. ERE-Vit-CAT, 2x-ERE-pS2-Luc, CMV-β-gal, HA-ubiquitin, and 
pBS/U6/CHIPi have been described previously (275). 
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 Cell Line\s 
  The human cervical carcinoma HeLa cell line and the breast cancer cell lines MCF7 and 
the ERα-negative MCF7-derived C4-12 cells (generously provided by Dr. W. Welshons, 
University of Missouri) are routinely maintained in our laboratory and have been 
described previously (23).  Before all experiments involving transient transfection and/or 
hormone treatment, cells were cultured in hormone-free medium (phenol red-free 
minimum Eagle’s medium (MEM) with 3% charcoal-stripped fetal bovine serum) for 2 d. 
 
Stable Transfection of ERα    
C4-12 cells were transfected with ERα constructs using LipofectAMINE/PLUS reagent 
and exposed to antibiotic (G418; 0.8mg/ml) for 3 weeks.  Multiple single G418-resistant 
clones were selected, expanded, and ERα levels were determined by immunoblot.   
 
Protein extraction, coimmunoprecipitation and immunoblot  
Soluble cell lysates were prepared in ER extraction lysis buffer (50mM Tris, pH 7.4, 
150mM NaCl, 5mM EDTA, 1% Triton X-100, ATPase inhibitors [1mM Na3O4V, 25mM 
NaF, 20μM MoNa2O4], and PIC III.  Receptor-chaperone complexes were 
immunoprecipitated with an ERα antibody (HC-20; Santa Cruz).  Complexes were 
pelleted with anti-rabbit IgG agarose beads (TrueBlot; eBiosciences).  Beads were 
washed in Tris-buffered saline (TBS) with ATPase inhibitors and 1mM PMSF.  Samples 
were boiled in 2xSDS loading buffer and proteins resolved by SDS-PAGE.  Western blot 
was performed using antibodies specific for ERα, Hsp90, CHIP, Bag1, and p23. To 
prepare nuclear extracts, cells were resuspended in hypotonic buffer (20mM HEPES, 
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 0.5mM MgCl2, 0.5mM DTT, 5mM KCl, 2mM CaCl2, 8.55% sucrose, 1mM PMSF) and 
cell membranes disrupted with in a Dounce homogenizer on ice (30 strokes using pestle 
B).  Fractured cells were centrifuged at 2500rpm for 10’ at 4ºC.  Nuclei pellets were 
washed 2 times with hypotonic buffer and nuclear extracts were prepared with ER 
extraction lysis buffer. 
 
Polyubiquitination assays   
HeLa cells were transiently transfected with ERα or ERα-AA and HA-tagged ubiquitin 
for 24h using LipofectAMINE/PLUS, according to manufacturer’s guidelines.   Cells 
were pretreated with 25μM MG132 for 1h to block proteasome activity.  Cells were then 
treated with DMSO, E2 (10nM), or ICI (100nM) for 4h. Following treatment, cells were 
lysed in ER extraction buffer.  500μg of lysate was precleared with protein G-agarose for 
30 min at 4°C and immunoprecipitated using anti-ERα antibody or IgG at 4°C overnight 
followed by addition of 30μl of protein G-agarose beads for 30 min.  Beads were briefly 
centrifuged, washed 3 times with TBS with 0.1M PMSF, and resuspended in 2xSDS 
loading buffer.  Proteins were separated by electrophoresis and transferred to PVDF 
membrane. Blots were probed for ubiquitinated ERα using ant-HA antibody.  
 
RNA interference (siRNA)  
siRNA transfection reagent Dharmafect1 and SMARTpool siRNA targeting Bag1, p23, 
and scrambled siRNA were purchased from Dharmacon. Bag1 and p23 siRNA were 
transfected into C4-12 cells according to the manufacturer’s protocol.  At 24 and 48 h, 
media was changed.  Seventy-two hours after transfection, cells were pretreated with 
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 DMSO or CHX (25μg/ml) then treated with or without GA (1μM) for the indicated times.  
Cells were lysed and Western blotting performed using specific antibodies.  CHIP siRNA 
was generated by transfection of pBS/U6/CHIPi plasmid into HeLa cells using 
LipofectAMINE/PLUS; pcDNA vector was used as non-targeting control, as described 
previously (275).  Mock transfection was transfection reagent only.     
 
Estrogen-responsive reporter gene assays  
For luciferase assays, C4-12 cells were transfected with 250ng 2xERE-ps2-Luc using 
Fugene.  Twenty-four hours later, media was changed and cells treated with E2 (10-16 to 
10-9 M) for 12 h. At the end of the experiment, cell lysates were prepared for reporter 
enzyme assays. Luciferase activity was determined using the Promega Luciferase Assay 
System.  Luciferase activity was normalized to β-gal activity as determined by the 
Galacto-Light Plus chemiluminescent reporter assay (Tropix Inc.).  For estrogen-
responsive chloramphenicol acetyltransferase (CAT) assays, C4-12 cells were transfected 
with 250ng ERE-CAT for 24 h using Fugene.  Media was then changed and cells treated 
with vehicle (DMSO) or E2 (10nM) for 48 h.  Cell lysates were prepared and protein 
quantified using the Bio-Rad BCA Protein Assay Kit.  100μg total protein from each 
treatment group was used to determine CAT levels with the colorimetric Roche CAT 
ELISA kit.  ERα expression, determined by immunoblot of vehicle treated cells, was 
quantified and used to adjust CAT levels to account for any slight difference in stable 
clone ERα expression level and eliminate any possibility that elevated CAT levels were 
due to elevated ERα expression in a clone.   
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 Quantitative Real-Time RT-qPCR  
Total RNA was prepared by RNAeasy Mini Kit (Qiagen), according to the protocol 
provided by the manufacturer.  RNA (2μg) was reverse-transcribed in a total volume of 
25μl containing 400U Molony murine leukemia virus reverse transcriptase (New England 
Biolabs), 400ng random hexamers (Promega), 80U Ribonuclease inhibitor and 1mM 
deoxynucleotide triphosphates.  The resulting cDNA was used in subsequent RT-qPCR 
performed in 20μl Roche LightCycler Mix with 5pmol forward and reverse primers for 
cathepsin D forward primer, 5’-GTACATGATCCCCTGTGAGAAGGT-3’; reverse 
primer, 5’-GGGACAGCTTGTAGCCTTTGC-3’ (183) and TaqMan primers for EF1α 
forward primer 5’-CTGAACCATCCAGGCCAAAT-3’; reverse primer 5’-
GCCGTGTGGCAATCCAAT-3’ and EF1α TaqMan probe 5’-FAM-
AGCGCCGGCTATGCCCCTG-TAMRA-3’.  The relative concentration of mRNA was 
calculated using the ΔΔCt method according to Relative Quantitation of Gene Expression 
(Applied Biosystems) with EF1α mRNA as an internal control. 
 
Quantification and Statistical Analysis  
Films were quantified with ImageJ software (http://rsb.info.nih.gov/ij/).  Statistical 
analyses were performed using Prism software. P-values were determined by Student’s t-
test and ANOVA.  EC50 values were calculated using sigmoidal dose-response curve-fit 
analysis.  
105
 IDENTIFICATION OF ESTROGEN RECEPTOR ALPHA UBIQUITINATION 
SITES BY MASS SPECTROMETRY 
 
ABSTRACT 
Transcriptional activity and stability of estrogen receptor alpha (ER) are tightly regulated 
by several mechanisms, including post-translational modifications.  For example, serine, 
threonine, and tyrosine residues can be targeted for phosphorylation, while lysine 
residues are substrates for acetylation and ubiquitination.  The ER lysine residue(s) 
targeted for ubiquitination have not yet been identified.  Mass spectrophotometry (MS) is 
a powerful technique capable of detecting increases in the molecular weight of proteins 
due to the addition of various post-translational modifications (PTMs).  The purpose of 
this study was to utilize MS to span the ER protein sequence and reveal amino acid (AA) 
residues targeted for phosphorylation, acetylation, and ubiquitination.  ERα peptide 
(Panvera, Carlsbad, CA) was resolved by SDS-PAGE and visualized with Coomassie 
blue staining.  A 66kDa band corresponding to ERα was extracted, reduced with 
dithiothreitol and alkylated with iodoacetamide.  ERα was then digested overnight with 
trypsin.  The resulting peptides were subjected to liquid chromatography followed by MS 
using an UltiMate-nano liquid chromatograph (LC Packings, Sunnyvale, CA) coupled to 
a Finnigan LCQ Deca XP MAX LC/MS (Thermo, Franklin, MA).  Resulting sequences 
were analyzed using MASCOT, and fragments meeting the MASCOT 95% confidence 
score were considered as ERα with a PTM.  Several phosphorylated ER fragments were 
identified, as indicated by an 80Da increase in molecular mass.  Peptides containing AAs 
S167, S282, S559, and T563 were phosphorylated.  Of these AA residues, only S167 has 
106
been previously reported to be phosphorylated; the other phosphorylated AAs may be 
unique to this insect cell-expressed form of the receptor (the Panvera ERα peptide is 
expressed in SF9 cells).  Acetylation at the N-terminus of ERα, as indicated by a 42Da 
mass increase, was also observed.  Previous reports have shown ER to be preferentially 
acetylated at lysines 266 and 268 or lysines 302 and 303, suggesting N-terminal 
acetylation may also be related to SF9 cell expression.  Using the MS approach, 
ubiquitinated lysine residues were not detected, perhaps due to the inherent instability 
and insolubility of ubiquitinated proteins.  In conclusion, this is the first report using MS 
to identify alternative phosphorylation and acetylation sites on ERα.  MS is a direct 
approach for visualizing PTMs and may be useful for identifying additional 
modifications on ERα and other members of the nuclear receptor superfamily. 
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METHODS:  
Instrumentation  
Ultimate nano-LC (LC Packings) 
LCQ Deca XP (Thermo Finnigan)  
Sample Preparation  
The complexity of MCF7 proteome was reduced as follows to enrich for ERα.  Whole 
cell extracts were prepared from MCF7 cells previously serum starved in 3% csFBS for 3 
days, pretreated with MG132 (25uM) for 1 hour, and treated with or without 17β-
estradiol (10nM) or Fulvestrant  (ICI 182, 780; 100nM) for 4 hours.  5 x 1mg protein 
from each treatment group was diluted at least 10-fold in TBS with PMSF (10μM).  
Samples were precleared with normal rabbit IgG and immunoprecipitated with ERα 
antibody (HC-20, Santa Cruz) followed by protein-G-agarose beads. ERα protein was 
resolved by SDS-PAGE and visualized with Coomassie stain. Gel slices were excised, 
reduced with DTT, alkylated with iodoacetmide, and digested with pepsin or trypsin 
(proteomics grade; Sigma). From this digest, samples were dried and reconstituted in 
10ul of 0.1% formic acid in preparation for LC-MS/MS.  
To enrich for ubiquitinated ERα, immunoprecipitated samples were further purified 
through a ubiquitin enrichment kit (Pierce) before SDS-PAGE. Commercially available 
column-purified ERα (Panvera/Invitrogen) was also analyzed by LC-MS/MS to 
determine the maximum possible sequence coverage for this protein.  
Electrospray Conditions:  
108
Trypsin digests were resolved on a 60 minute reversed-phase gradient using an Ultimate 
nano-LC coupled to a LCQ-Deca XP mass spectrometer. 
Mass spectrometry Analysis  
MS data were submitted to Mascot (http://www.matrixscience.com)  
And searched against human proteins to obtain peptide sequence, identification, and post-
translational modifications.  Variable modifications of acetylation (K, protein N-term), 
carbamido methyl (C), oxidation (M), phosphorylation (S, T, Y), and ubiquitination (K) 
were considered during the search.  Peptides with Mascot scores above 30 were retained 
as true hits.  
 
Suggested improvements on purification techniques: 
Improve protein extraction 
Further improvements are necessary to increase the yield and purity of ubiquitinated 
ERα.  The difficulty thus far has been the isolation of sufficient ubiquitinated ER species 
in a manner that is conducive to immunopurification.  Ubiquitinated ER is only partially 
soluble under conditions that are suitable for immunopurification.   
Ubiquitinated ER is not efficiently extracted by gentle lysis buffers; ER extraction 
buffer (Triton X-100) and RIPA buffer (Triton + NP40 + 0.2% SDS) extract sufficient 
ubiquitinated ERα to detect by Western blot but not efficiently enough for high yield.  I 
have had some success with strong lysis buffer containing 2% SDS.  Although this lysis 
buffer is not suitable for immunoprecipitation, dilution of protein lysates to 0.2% SDS 
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using SDS-free buffers (using RIPA without SDS or ER extraction buffer) allows 
immunopurification of these SDS-extracted species.  An alternative strategy is to utilize 
multiple detergents in concentrations that are still suitable for immunopurification (NP40, 
deoxycholate, IGEPAL, 0.2% SDS, Triton X-100, etc).  The proper conditions must be 
determined empirically.  Isolation of ER under stringent conditions followed by dilution 
or dialysis into buffer that maintains receptor solubility while allowing purification is a 
critical step during the optimizing of this process.   
Concentration of proteins 
ERα comprises only ~0.2% of cell protein (~30-60 fmol/mg total protein).  Ubiquitinated 
receptor forms are even less abundant.  Orders of magnitude of concentration and 
purification must be accomplished in order to acquire µg quantities of ubiquitinated ERα 
for mass spectrometry.  Proteins may be concentrated to allow volume reduction and 
prepare samples for running on SDS-PAGE to separate purified proteins.  Millipore 
columns with 20,000 kDa MW cutoff membranes are available as centrifugation columns 
in various sizes.  An unfortunate consequence of using Triton X-100 detergents is the 
creation of detergent micelles when Triton X-100 concentration exceeds 5%.  This 
limitation reduces the ability to concentrate samples that contain Triton X-100.  Protein 
purification techniques such as acetone or TCA/TFA-mediated protein precipitation, 
FPLC, HPLC, ion-exchange, or other column approaches may be employed but have not 
been explored thus far.   
Alternative purification strategies that do not rely on antibodies may circumvent 
immunopurification limitations.  His-tagged-UBR7-conjugated ER may be purified on 
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nickel or cobalt (Talon) columns under much more stringent conditions (high salt, higher 
detergent) that would allow ubiquitinated ER to be purified under conditions where the 
receptors remain soluble.  This would require transient transfection of His6-UBR7 into 
MCF7 cells by Fugene6 transfection.  Stable transfected UBR7 cells have not been 
created; long-term blockade of ubiquitin chain formation is likely toxic to cells.  
Large scale purification 
Batch-style purification is necessary to optimize conditions before scale-up.  
However, scale-up by running numerous batches is time-consuming and less efficient 
than a column-based approach.  A column of FLAG-beads or ER antibody + protein-G 
beads may be utilized. Elution using 3xFLAG or other methods that retain 
immunopurification capability would allow eluted ER proteins to be further purified on 
an ubiquitin bead-based column.  Denaturing elution using SDS followed by 
concentration with Millipore Zip-tips or centrufigation columns would concentrate 
samples to small (µl) volumes that will fit into SDS-PAGE wells. 
Block deubiquitin enzyme activity 
The addition of deubiquitin enzyme (DUB) inhibitors such as NEM to MG132-
treated cells may further enhance ubiquitinated forms of ERα.  Alternatively, ubiquitin-
aldehyde or ubiquitin-vinyl sulfone to protein extracts would also inhibit DUB activity.  I 
have purchased NEM (Sigma) but have not compared the effect of DUB inhibition to 
MG132 action.  Boston Biochem sells the ubiquitin derivatives. 
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CONCLUSIONS 
LC-MS/MS was capable of detecting 37 distinct ERα fragments which corresponds to 
56.3% sequence coverage.  Phosphorylation and acetylation were readily detectable with 
this method.  Ubiquitin proteins were detected, as well as ubiquitinated species for 
abundant proteins such as cytokeratins.   Optimization of the purification scheme may 
yield higher quality ERα protein. ERα  may then be more fully investigated for PTMs 
after treatment with 17β-estradiol,  Fulvestrant, and other ligands known to induce PTMs 
on ERα.  LC-MS/MS is a promising tool for identifying the PTMs involved in ERα 
regulation.    
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ENRICHMENT PROCEDURE 
1. MCF7 cells 
 
2. WCE 
 
3. Preclear  
 
4. IP/enrich 
 
5. SDS-PAGE 
 
6. Band excision 
 
7. Trypsin digest 
 
8. LC separation 
 
9. Mass spectrometry 
 
10. MASCOT analysis 
Figure 10. Purification of ERα.  
Panel A) MCF7 cells serum starved for 3d in 3% csFBS were pretreated with MG132 
(M, 25uM) for 1hr followed by treatment with E2 (ME, 10nM) or Fulvestrant (MI, 
100nM) for 4hrs.  ERα levels were detected by Western blot before and after 
immunoprecipitation with ERα antibody. Purification.   
Panel B) Further enrichment of ubiquitinated species of ERα was achieved  by 
ubiquitin affinity purification following ERα immunoprecipitation.   
Panel C) Western blot for ERα after each.  Ubiquitinated species of ERα were detected 
in ERα immunoprecipitated samples and ubiquitin enriched samples by Western blot 
using an anti-ubiquitin antibody (FK2; Biomol).   
Panel D) ERα immunoprecipitated samples and ubiquitin enriched samples were 
resolved by SDS-PAGE and stained with silver stain before gel extraction.   
Panel E) Purified ERα (baculovirus-infected, insect cell-derived; Panvera/Invitrogen) 
was also investigated by mass spectrometry 
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 Complete ERα Amino Acid Sequence:   
29 lysines 
 
MTMTLHTKASGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPAVYNY
PEGAAYEFNAAAAANAQVYGQTGLPYGPGSEAAAFGSNGLGGFPPLNSVSPSPL
MLLHPPPQLSPFLQPHGQQVPYYLENEPSGYTVREAGPPAFYRPNSDNRRQGGR
ERLASTNDKGSMAMESAKETRYCAVCNDYASGYHYGVWSCEGCKAFFKRSIQ
GHNDYMCPATNQCTIDKNRRKSCQACRLRKCYEVGMMKGGIRKDRRGGRML
KHKRQRDDGEGRGEVGSAGDMRAANLWPSPLMIKRSKKNSLALSLTADQMVS
ALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLT
LHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEGMVEI
FDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVL
DKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKN
VVPLYDLLLEMLDAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQKYYITG
EAEGFPATV 
 
 
 
Complete ERβ amino acid sequence: 
 
30 lysines 
 
MDIKNSPSSLNSPSSYNCSQSILPLEHGSIYIPSSYVDSHHEYPAMTFYSPAVMNYS
IPSNVTNLEGGPGRQTTSPNVLWPTPGHLSPLVVHRQLSHLYAEPQKSPWCEARS
LEHTLPVNRETLKRKVSGNRCASPVTGPGSKRDAHFCAVCSDYASGYHYGVWS
CEGCKAFFKRSIQGHNDYICPATNQCTIDKNRRKSCQACRLRKCYEVGMVKCG
SRRERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTL
LEAEPPHVLISRPSAPFTEASMMMSLTKLADKELVHMISWAKKIPGFVELSLFDQ
VRLLESCWMEVLMMGLMWRSIDHPGKLIFAPDLVLDRDEGKCVEGILEIFDMLL
ATTSRFRELKLQHKEYLCVKAMILLNSSMYPLVTATQDADSSRKLAHLLNAVT
DALVWVIAKSGISSQQQSMRLANLLMLLSHVRHASNKGMEHLLNMKCKNVVP
VYDLLLEMLNAHVLRGCKSSITGSECSPAEDSKSKEGSQNPQSQ 
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 Alignment:  http://bioweb2.pasteur.fr/intro-en.html 
 Program:  needle 
 Align_format: srspair 
# Report_file: outfile.align 
 
 Aligned_sequences: 2 
 Matrix: EBLOSUM62 
 Gap_penalty: 1.0 
 Extend_penalty: 2.0 
 
 Length: 635 
 Identity:     297/635 (46.8%) 
 Similarity:   396/635 (62.4%) 
 Gaps:         145/635 (22.8%) 
 Score: 1538.0 
Shared 14 (or 15) lysines 
 
ERα  206  210  231  235  244  252  362   401   416   449  472*  492  520  529  531 
        |     |     |     |     |     |     |      |     |     |      |      |     |     |     | 
ERβ  170  174  195  199  208  216  314   353   368   401  443*  471  480  482  504 
 
 
Figure 11.  14 lysine residues align perfectly between ERα and ERβ 
Summary of needle pairwise alignment performed in Figure 11.  * is a potential 15th 
lysine pair that are one amino acid away from alignment. (http://bioweb2.pasteur.fr/intro-
en.html) 
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Query Obs Mr(exp) Mr(cal) Delta Miss Score Rank Peptide
2111 747.89 2240.63 2239.82 0.81 6 22 1 YSEYDPTRPFSEASMMGL  + 2 Phospho (ST)
971 576.76 1151.51 1150.67 0.84 3 27 1 KIPLERPLGE
1424 781.85 1561.68 1560.67 1.01 5 36 1 YSEYDPTRPFSEA
1413 1552.88 1551.87 1551.72 0.15 5 37 1 QVYGQTGLPYGPGSE
446 867.65 866.64 866.47 0.17 3 39 1 LDAEPPIL
1511 831.61 1661.2 1659.8 1.4 6 40 1 SPFLQPHGQQVPYY
852 540.73 1079.45 1078.61 0.84 4 45 1 LEPLNRPQL
1370 746.3 1490.59 1489.64 0.96 4 51 1 YSEYDPTRPFSE
 
 
 
 
 
Figure 12.  MASCOT results from purified ERα (Panvera). 47.4% coverage was 
achieved by trypsin digest (upper panel). 12.4% coverage was achieved by pepsin digest 
(middle panel). Total coverage was 56.3% . A total of 37 unique peptide fragments were 
identified by LC-MS/MS.  MASCOT results from MCF7-extracted ERα (lower panel). 
Query Obs Mr(exp) Mr(cal) Delta Miss Score Rank Peptide
2032 671.03 1340.05 1339.73 0.32 0 33 1 AANLWPSPLMIK
2038 861.03 1720.04 1719.72 0.32 1 35 1 LASTNDKGSMAMESAK  + Phospho (ST) 
1913 643.38 1284.75 1283.76 0.99 0 52 1 LLFAPNLLLDR
2423 1064.68 2127.35 2126.16 1.19 0 55 1 LHQIQGNELEPLNRPQLK
1502 640.8 1279.58 1278.68 0.9 0 60 1 AGLTLQQQHQR
1951 821.43 1640.84 1639.75 1.09 1 80 1 LASTNDKGSMAMESAK
Query Obs Mr(exp) Mr(cal) Delta Miss Score Rank Peptide
1282 550.9 1099.78 1098.55 1.23 0 46 1 AANLWPSPLM
1502 640.8 1279.58 1278.68 0.9 0 70 1 AGLTLQQQHQR
2695 887.34 2658.98 2658.38 0.6 0 75 1 ASGMALLHQIQGNELEPLNRPQLK
1131 1001.49 1000.48 999.39 1.1 0 58 1 CYEVGMMK  + Pyro-cmC (N-term camC) [-17.03] 
2003 844.44 1686.87 1686.63 0.24 0 48 1 DDGEGRGEVGSAGDMR  + Phospho (ST) 
2180 931.22 1860.43 1860.77 -0.34 0 58 1 DSSKPAVYNYPEGAAYE
1432 610.52 1219.03 1217.58 1.45 0 63 1 EAGPPAFYRPN
1451 1240.6 1239.59 1239.64 -0.05 0 47 1 ELVHMINWAK
2635 1293.41 2584.81 2584.2 0.61 0 92 1 GGASVEETDQSHLATAGSTSSHSLQK 
2397 1051.23 2100.44 2099.98 0.46 0 70 1 GQQVPYYLENEPSGYTVR
2332 1007.87 2013.73 2014.06 -0.33 0 69 1 HQIQGNELEPLNRPQLK
1174 512.61 1023.21 1022.58 0.64 0 41 1 IPLERPLGE
1045 463.74 925.47 924.53 0.95 0 53 1 ITDTLIHL
1951 821.43 1640.84 1639.75 1.09 0 93 1 LASTNDKGSMAMESAK
2423 1064.68 2127.35 2126.16 1.19 0 73 1 LHQIQGNELEPLNRPQLK
1514 643.84 1285.67 1284.74 0.93 0 48 1 LLFAPNLLLDR
2628 1288.51 2575.01 2574.25 0.76 0 61 1 LQPHGQQVPYYLENEPSGYTVR
1418 604.9 1207.78 1206.61 1.17 0 57 1 PLGEVYLDSSK
2179 930.95 1859.88 1858.99 0.89 0 53 1 QIQGNELEPLNRPQLK  + Pyro-glu (N-term Q) [-17.03] 
2539 1177.46 2352.9 2351.99 0.91 0 61 1 SIQGHNDYMCPATNQCTIDK
2675 875.41 2623.2 2623.1 0.11 0 54 1 SIQGHNDYMCPATNQCTIDKNR
1670 691.55 1381.08 1379.8 1.28 0 58 1 VLDKITDTLIHL
2023 571.34 1711 1710.93 0.07 0 49 1 VLDKITDTLIHLMAK
2482 1118.8 2235.58 2236.02 -0.44 0 48 1 VYLDSSKPAVYNYPEGAAYE
1408 602.52 1203.03 1201.52 1.51 0 57 1 YASGYHYGVW
2386 1043.28 2084.55 2084.8 -0.25 0 58 1 YCAVCNDYASGYHYGVW
2733 936.5 2806.46 2807.08 -0.61 0 52 1 YCAVCNDYASGYHYGVWSCEGCK
1808 760.34 1518.66 1516.71 1.95 0 47 1 YYITGEAEGFPATV
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Figure 13. Summarized sequence coverage for ERα.  56.3% of ER (335/595 amino 
acids) was covered by trypsin digest.  Yellow and green indicate two independent digests 
and analyses.  Long spans of hydrophobic residues prevented extensive coverage.  Long 
spans of hydrophobic residues and lack trypsin-sensitive residues, thus preventing more 
extensive covereage.  Lysines are highlighted in red.  S167 and K302/303 are bolded for 
orientation.  * indicates PTM detected (phosphorylation of S167).  A total of 63 peptide 
fragments were resolved by LC-MS/MS.  (Top panel).   *indicates PTM detected. 
 
 
M*TMTLHTKASGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPAVYNYPEGAAYEFNAAAAANA
QVYGQTGLPYGPGSEAAAFGSNGLGGFPPLNSVSPSPLMLLHPPPQLSPFLQPHGQQVPYYLENEPSGYTV
REAGPPAFYRPNSDNRRQGGRERLAS*TNDKGSMAMESAKETRYCAVCNDYASGYHYGVWSCEGCKAFFKR
SIQGHNDYMCPATNQCTIDKNRRKSCQACRLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGS
*AGDMRAANLWPSPLMIKRSKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADR
ELVHMINWAKRVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEGMVE
IFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAG
LTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLLEMLDAHRLHAPTSRGGAS*VEET*
DQSHLATAGSTSSHSLQKYYITGEAEGFPAT 
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Figure 14 A) LC-MS base peak chromatogram for trypsin digest of ESR1. B) MS/MS spectrum of 
precursor m/z 821.40 at retention time 19.10 minutes. Strong peaks are labeled with m/z values and 
fragment ions corresponding to the peptide LASTNDKGSMAMESAK. C) MS/MS spectrum of precursor 
m/z 861.00 at retention time 20.08 minutes. Peak at m/z 812.4 corresponds to the 98 Da neutral loss 
ion expected from a phosphoserine residue. D) same as C. with vertical scale expanded 10-fold to 
show sequence-specific fragment ions corresponding to LApSTNDKGSMAMESAK. Note that the y142+
fragment appears 9 m/z lower in D. due to the loss of H3PO4 from the phosphoserine residue (18 Da
less than an unmodified serine residue).
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MG132  Score     Accession #        Name 
K2C6A_HUMAN    651              P02538                  Keratin, type II cytoskeletal 6A Cytokeratin 6A CK 6A K6a keratin  
K2C5_HUMAN    445              P13647                  Keratin, type II cytoskeletal 5 Cytokeratin 5 K5 CK 5 58 kDa cytokeratin  
HS90A_HUMAN    268              P07900                  Heat shock protein HSP 90alpha HSP 86  
K1CO_HUMAN    244              P19012                  Keratin, type I cytoskeletal 15 Cytokeratin 15 K15 CK 15  
ALBU_HUMAN    214              P02768                  Serum albumin precursor  
CH60_HUMAN    206              P10809                  60 kDa heat shock protein, mitochondrial precursor Hsp60 60 kDa chaperonin CPN60 He  
K2C4_HUMAN    154              P19013                  Keratin, type II cytoskeletal 4 Cytokeratin 4 K4 CK4  
FLNA_HUMAN    152              P21333                  Filamin A Alphafilamin Filamin 1 Endothelial actinbinding protein Actinbinding p  
HS90B_HUMAN      93              P08238                  Heat shock protein HSP 90beta HSP 84 HSP 90  
K1CM_HUMAN      86              P13646                  Keratin, type I cytoskeletal 13 Cytokeratin 13 K13 CK 13  
TRAP1_HUMAN      80              Q12931                 Heat shock protein 75 kDa, mitochondrial precursor HSP 75 Tumor necrosis factor type 1  
ESR1_HUMAN      69              P03372                  Estrogen receptor ER Estradiol receptor ERalpha  
K1CN_HUMAN      65              P02533                  Keratin, type I cytoskeletal 14 Cytokeratin14 CK14 Keratin14 K14  
UBIQ_HUMAN      62              P62988                  Ubiquitin  
HNRPR_HUMA     60              O43390                 Heterogeneous nuclear ribonucleoprotein R hnRNP R  
HA25_HUMAN      53              P01907                  HLA class II histocompatibility antigen, DQ5 alpha chain precursor DC1 alpha chain  
OST5_HUMAN      49              Q8IZT8                 Heparan sulfate glucosamine 3Osulfotransferase 5 EC 2.8.2.23 Heparan sulfate Dglucos  
S10A9_HUMAN      48              P06702                  Calgranulin B Migration inhibitory factorrelated protein 14 MRP14 P14 Leukocyte L  
CEL_HUMAN      46              P19835                  Bilesaltactivated lipase precursor EC 3.1.1.3 EC 3.1.1.13 BAL Bilesaltstimulate  
MG132 + E2  Score     Accession #        Name  
FAS_HUMAN    1308           P49327                   Fatty acid synthase EC 2.3.1.85 Includes Acylcarrierprotein Sacetyltransferase E  
TKT_HUMAN      300           P29401                   Transketolase EC 2.2.1.1 TK  
PRKDC_HUMA     249           P78527                   DNAdependent protein kinase catalytic subunit EC 2.7.1.37 DNAPKcs DNPK1 p460  
CO1A1_HUMAN       216           P02452                   Collagen alpha 1I chain precursor  
HNRPU_HUMA      185           Q00839                  Heterogenous nuclear ribonucleoprotein U hnRNP U Scaffold attachment factor A SAFA  
DHX9_HUMAN      129           Q08211                  ATPdependent RNA helicase A Nuclear DNA helicase II NDH II DEAHbox protein 9  
K22O_HUMAN      121           Q01546                  Keratin, type II cytoskeletal 2 oral Cytokeratin 2P K2P CK 2P  
IQGA1_HUMAN      103           P46940                   Ras GTPaseactivatinglike protein IQGAP1 p195  
ESR1_HUMAN        92           P03372                   Estrogen receptor ER Estradiol receptor ERalpha  
TOP2B_HUMAN        81           Q02880                  DNA topoisomerase 2beta EC 5.99.1.3 DNA topoisomerase II, beta isozyme  
UBIQ_HUMAN        81           P62988                   Ubiquitin  
SYV2_HUMAN        60           P26640                   ValyltRNA synthetase 2 EC 6.1.1.9 ValinetRNA ligase 2 ValRS 2 G7a  
LPPRC_HUMAN        59           P42704                   130 kDa leucinerich protein LRP 130 GP130 Leucinerich PPRmotif containing protein  
TRY1_HUMAN        47           P07477                   Trypsin I precursor EC 3.4.21.4 Cationic trypsinogen  
CO3A1_HUMAN        45           P02461                   Collagen alpha 1III chain precursor  
MG132 + ICI  Score      Accession #       Name 
ESR1_HUMAN  2835             P03372                   Estrogen receptor ER Estradiol receptor ERalpha  
K1CJ_HUMAN  1355             P13645                   Keratin, type I cytoskeletal 10 Cytokeratin 10 K10 CK 10  
K2C1_HUMAN  1036             P04264                   Keratin, type II cytoskeletal 1 Cytokeratin1 CK1 Keratin1 K1 67 kDa cytokerati  
K1CP_HUMAN    556             P08779                   Keratin, type I cytoskeletal 16 Cytokeratin 16 K16 CK 16  
K2C8_HUMAN    322             P05787                   Keratin, type II cytoskeletal 8 Cytokeratin 8 K8 CK 8  
EPIPL_HUMAN    290             P58107                   Epiplakin 450 kDa epidermal antigen  
K1CS_HUMAN    226             P08727                   Keratin, type I cytoskeletal 19 Cytokeratin 19 K19 CK 19  
K2C6B_HUMAN    181             P04259                   Keratin, type II cytoskeletal 6B Cytokeratin 6B CK 6B K6b keratin  
K1C9_HUMAN    117             P35527                   Keratin, type I cytoskeletal 9 Cytokeratin9 CK9 Keratin9 K9  
K2C3_HUMAN    114             P12035                   Keratin, type II cytoskeletal 3 Cytokeratin 3 K3 CK3 65 kDa cytokeratin  
MYH9_HUMAN    111             P35579                   Myosin heavy chain, nonmuscle type A Cellular myosin heavy chain, type A Nonmuscle myos  
K22E_HUMAN      89             P35908                   Keratin, type II cytoskeletal 2 epidermal Cytokeratin2e K2e CK 2e  
K1CT_HUMAN      70             P35900                   Keratin, type I cytoskeletal 20 Cytokeratin 20 K20 CK 20 Protein IT  
K2C6C_HUMAN      67             P48666                   Keratin, type II cytoskeletal 6C Cytokeratin6C CK 6C K6c keratin  
UBIQ_HUMAN      45             P62988                   Ubiquitin  
 
Figure 15. ER interacting proteins identified with mass spectrometry.  
Combined results from wtERα and ERα-AA from MG132, MG132 +E2, and MG132 + ICI  
ERα and ubiquitin were detected in all samples.  Similar protein profiles were detected for both 
wtERα and ERα-AA complexes.  
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